Walgreens Boots Alliance (WBA) 10-Q 5 Apr 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Feb. 29, 2016	Mar. 31, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Walgreens Boots Alliance, Inc.
Entity Central Index Key	1,618,921
Current Fiscal Year End Date	--08-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		1,080,245,720
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Feb. 29, 2016

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions		Feb. 29, 2016	Aug. 31, 2015
Current Assets:
Cash and cash equivalents		$ 3,586	$ 3,000
Accounts receivable, net		6,733	6,849
Inventories		9,025	8,678
Other current assets		1,034	1,130
Total Current Assets		20,378	19,657
Non-Current Assets:
Property, plant and equipment, at cost, less accumulated depreciation and amortization		14,552	15,068
Goodwill		15,796	16,372
Intangible assets		11,122	12,351
Other non-current assets		4,537	5,334
Total Non-Current Assets		46,007	49,125
Total Assets		66,385	68,782
Current Liabilities:
Short-term borrowings		1,052	1,068
Trade accounts payable		9,873	10,088
Accrued expenses and other liabilities		5,050	5,225
Income taxes		297	176
Total Current Liabilities		16,272	16,557
Non-Current Liabilities:
Long-term debt	[1]	12,974	13,315
Deferred income taxes		3,107	3,538
Other non-current liabilities		4,114	4,072
Total Non-Current Liabilities		$ 20,195	$ 20,925
Commitments and Contingencies (see Note 12)
Equity:
Preferred stock $.01 par value; authorized 32 million shares, none issued		$ 0	$ 0
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at February 29, 2016 and August 31, 2015		12	12
Paid-in capital		10,041	9,953
Employee stock loan receivable		(1)	(2)
Retained earnings		26,348	25,089
Accumulated other comprehensive (loss) income		(1,868)	(214)
Treasury stock, at cost; 92,853,639 shares at February 29, 2016 and 82,603,274 at August 31, 2015		(5,026)	(3,977)
Total Walgreens Boots Alliance, Inc. Shareholders' Equity		29,506	30,861
Noncontrolling interests		412	439
Total Equity		29,918	31,300
Total Liabilities and Equity		$ 66,385	$ 68,782
[1]	All notes are presented net of unamortized discount and debt issuance costs, where applicable.

CONSOLIDATED CONDENSED BALANCE3

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Feb. 29, 2016	Aug. 31, 2015
Equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	32,000,000	32,000,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized shares (in shares)	3,200,000,000	3,200,000,000
Common stock, issued (in shares)	1,172,513,618	1,172,513,618
Treasury stock, at cost (in shares)	92,853,639	82,603,274

CONSOLIDATED CONDENSED STATEMEN

CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) - 6 months ended Feb. 29, 2016 - USD ($) $ in Millions	Common Stock [Member]	Treasury Stock [Member]	Paid-In Capital [Member]	Employee Stock Loan Receivable [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Noncontrolling Interests [Member]	Total
Beginning Balance at Aug. 31, 2015	$ 12	$ (3,977)	$ 9,953	$ (2)	$ (214)	$ 25,089	$ 439	$ 31,300
Beginning Balance (in shares) at Aug. 31, 2015	1,089,910,344
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 0	0	0	0	0	2,040	9	2,049
Other comprehensive income (loss), net of tax	0	0	0	0	(1,654)	0	(36)	(1,690)
Dividends declared ($0.72 per share)	0	0	0	0	0	(781)	0	(781)
Treasury stock purchases	$ 0	(1,152)	0	0	0	0	0	(1,152)
Treasury stock purchases (in shares)	(13,815,558)
Employee stock purchase and option plans	$ 0	103	28	0	0	0	0	131
Employee stock purchase and option plans (in shares)	3,565,193
Employee stock loan receivable	$ 0	0	0	1	0	0	0	1
Stock-based compensation	0	0	60	0	0	0	0	60
Ending Balance at Feb. 29, 2016	$ 12	$ (5,026)	$ 10,041	$ (1)	$ (1,868)	$ 26,348	$ 412	$ 29,918
Ending Balance (in shares) at Feb. 29, 2016	1,079,659,979

CONSOLIDATED CONDENSED STATEME5

CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) [Abstract]
Cash dividends declared (in dollars per share)	$ 0.3600	$ 0.3375	$ 0.7200	$ 0.6750

CONSOLIDATED CONDENSED STATEME6

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (UNAUDITED) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (UNAUDITED) [Abstract]
Net sales	$ 30,184	$ 26,573	$ 59,217	$ 46,127
Cost of sales	22,240	19,691	43,771	33,949
Gross Profit	7,944	6,882	15,446	12,178
Selling, general and administrative expenses	6,084	5,606	12,118	10,062
Equity earnings in Alliance Boots	0	101	0	315
Operating Income	1,860	1,377	3,328	2,431
Gain on previously held equity interest	0	706	0	706
Other income (expense)	(496)	504	(553)	703
Earnings Before Interest and Income Tax Provision	1,364	2,587	2,775	3,840
Interest expense, net	140	144	278	199
Earnings Before Income Tax Provision	1,224	2,443	2,497	3,641
Income tax provision	301	391	468	712
Post tax earnings from equity method investments	9	8	20	8
Net Earnings	932	2,060	2,049	2,937
Net earnings attributable to noncontrolling interests	2	18	9	45
Net Earnings Attributable to Walgreens Boots Alliance, Inc.	$ 930	$ 2,042	$ 2,040	$ 2,892
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - basic (in dollars per share)	$ 0.86	$ 1.96	$ 1.88	$ 2.91
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - diluted (in dollars per share)	0.85	1.93	1.87	2.88
Dividends declared per share (in dollars per share)	$ 0.3600	$ 0.3375	$ 0.7200	$ 0.6750
Average shares outstanding (in shares)	1,080.2	1,043.6	1,084.6	994.7
Dilutive effect of stock options (in shares)	8.2	11.1	8.9	10.6
Average diluted shares (in shares)	1,088.4	1,054.7	1,093.5	1,005.3

CONSOLIDATED CONDENSED STATEME7

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) [Abstract]
Net Earnings	$ 932	$ 2,060	$ 2,049	$ 2,937
Other comprehensive income (loss), net of tax:
Pension/postretirement obligations	(2)	(8)	1	(9)
Unrealized gain (loss) on cash flow hedges	1	0	2	(12)
Unrecognized gain (loss) on available-for-sale investments	(88)	90	(87)	189
Share of other comprehensive income (loss) of Alliance Boots	0	92	0	113
Currency translation adjustments	(1,156)	(301)	(1,606)	(490)
Total Other Comprehensive Income (Loss)	(1,245)	(127)	(1,690)	(209)
Total Comprehensive Income (Loss)	(313)	1,933	359	2,728
Comprehensive income (loss) attributable to noncontrolling interests	(33)	13	(27)	40
Comprehensive Income (Loss) Attributable to Walgreens Boots Alliance, Inc.	$ (280)	$ 1,920	$ 386	$ 2,688

CONSOLIDATED CONDENSED STATEME8

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
Cash Flows from Operating Activities:
Net earnings	$ 2,049	$ 2,937
Adjustments to reconcile net earnings to net cash provided by operating activities -
Depreciation and amortization	824	826
Change in fair value of warrants and related amortization	586	(859)
Gain on previously held equity interest	0	(706)
Deferred income taxes	(171)	181
Stock compensation expense	60	65
Equity earnings from equity method investments	(20)	(315)
Other	196	322
Changes in operating assets and liabilities -
Accounts receivable, net	(152)	(391)
Inventories	(553)	106
Other current assets	33	21
Trade accounts payable	160	363
Accrued expenses and other liabilities	(79)	(20)
Income taxes	92	(99)
Other non-current assets and liabilities	60	(94)
Net cash provided by operating activities	3,085	2,337
Cash Flows from Investing Activities:
Additions to property, plant and equipment	(657)	(643)
Proceeds from sale leaseback transactions	60	562
Proceeds from sale of business	43	0
Proceeds from sale of other assets	85	17
Alliance Boots acquisition, net of cash received	0	(4,461)
Other business and intangible asset acquisitions, net of cash received	(86)	(92)
Purchases of short-term investments held to maturity	(30)	(29)
Proceeds from short-term investments held to maturity	36	29
Other	(3)	(91)
Net cash used for investing activities	(552)	(4,708)
Cash Flows from Financing Activities:
Proceeds (payments) of short-term borrowings, net	61	(330)
Proceeds from issuance of long-term debt	0	12,279
Payments of long-term debt	(81)	(7,817)
Stock purchases	(1,152)	(594)
Proceeds related to employee stock plans	129	293
Cash dividends paid	(787)	(642)
Other	(29)	(360)
Net cash (used for) provided by financing activities	(1,859)	2,829
Effect of exchange rate changes on cash and cash equivalents	(88)	(99)
Changes in Cash and Cash Equivalents:
Net increase in cash and cash equivalents	586	359
Cash and cash equivalents at beginning of period	3,000	2,646
Cash and cash equivalents at end of period	$ 3,586	$ 3,005

Organization

Organization	6 Months Ended
	Feb. 29, 2016
Organization [Abstract]
Organization	Note 1. Organization Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance”) and subsidiaries are a global pharmacy-led health and wellbeing enterprise. Its operations are conducted through three reportable segments (Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale). See Note 18, Segment Reporting for further information. On December 31, 2014, Walgreens Boots Alliance became the successor of Walgreen Co. (“Walgreens”) pursuant to a merger designed to effect a reorganization of Walgreens into a holding company structure (the “Reorganization”). Pursuant to the Reorganization, Walgreens became a wholly-owned subsidiary of Walgreens Boots Alliance, a Delaware corporation formed for the purposes of the Reorganization, and each issued and outstanding share of Walgreens common stock converted on a one-to-one basis into Walgreens Boots Alliance common stock. References to the “Company” refer to Walgreens Boots Alliance and its subsidiaries from and after the effective time of the Reorganization on December 31, 2014 and, prior to that time, to the predecessor registrant Walgreens and its subsidiaries, except as otherwise indicated or the context otherwise requires. On December 31, 2014, following the completion of the Reorganization, Walgreens Boots Alliance completed the acquisition of the remaining 55% of Alliance Boots GmbH (“Alliance Boots”) that Walgreens did not previously own (the “Second Step Transaction”) in exchange for £3.133 billion in cash and approximately 144.3 million shares of Walgreens Boots Alliance common stock. Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method immediately upon completion of the Second Step Transaction. For financial reporting and accounting purposes, Walgreens Boots Alliance was the acquirer of Alliance Boots. The consolidated financial statements (and other data) reflect the results of operations and financial position of Walgreens and its subsidiaries for periods prior to December 31, 2014 and of Walgreens Boots Alliance and its subsidiaries for periods from and after the effective time of the Reorganization on December 31, 2014. As part of the Second Step Transaction, the Company acquired the remaining 27.5% noncontrolling interest in Walgreens Boots Alliance Development GmbH (“WBAD”), a global sourcing enterprise established by the Company and Alliance Boots. The Company already owned a 50% direct ownership in WBAD and indirectly owned an additional ownership interest through its previous 45% investment in Alliance Boots, representing a direct and indirect economic interest of 72.5%. The Company’s acquisition of the remaining 27.5% effective ownership in WBAD as part of the Second Step Transaction was accounted for as an equity transaction as it has historically been consolidated by the Company. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (“AHID”), which is not a member of the Company’s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.

Accounting Policies

Accounting Policies	6 Months Ended
	Feb. 29, 2016
Accounting Policies [Abstract]
Accounting Policies	Note 2. Accounting Policies Basis of Presentation The consolidated condensed financial statements of Walgreens Boots Alliance included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The consolidated condensed financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned entities in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated. The Consolidated Condensed Balance Sheet as of February 29, 2016, the Consolidated Condensed Statements of Equity for the six-month period ended February 29, 2016, and the Consolidated Condensed Statements of Earnings, the Consolidated Condensed Statements of Comprehensive Income and the Consolidated Condensed Statements of Cash Flows for the three month and six month periods ended February 29, 2016 and February 28, 2015, have not been audited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015. In the opinion of the Company, the unaudited consolidated condensed financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company’s operations, net earnings for any interim period may not be comparable to the same interim period in previous years or indicative of net earnings for the full fiscal year. In addition, with respect to the Company’s Retail Pharmacy USA segment, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a “generic conversion.” In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on Retail Pharmacy USA segment’s sales, gross profit margins and gross profit dollars. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. For a discussion of the Company’s significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.

Restructuring

Restructuring	6 Months Ended
	Feb. 29, 2016
Restructuring [Abstract]
Restructuring	Note 3. Restructuring On April 8, 2015, the Walgreens Boots Alliance Board of Directors approved a plan to implement a new restructuring program (the “Cost Transformation Program”) as part of an initiative to reduce costs and increase operating efficiencies. The Cost Transformation Program implemented and built on the cost-reduction initiative previously announced by the Company on August 6, 2014 and included plans to close approximately 200 stores across the U.S.; reorganize corporate and field operations; drive operating efficiencies; and streamline information technology and other functions. The Company incurred pre-tax charges of $28 million and $118 million related to the Cost Transformation Program during the three and six months ended February 29, 2016. $660 million ($254 million in real estate costs, $248 million related to asset impairment charges and $158 million in severance and other business transition and exit costs) related to the Cost Transformation Program. All charges related to the Cost Transformation Program have been recorded within selling, general and administrative expenses. In March 2014, the Walgreens Board of Directors approved a plan to close underperforming stores in efforts to optimize and focus resources in a manner intended to increase stockholder value. As of August 31, 2015, this plan was completed and no additional charges related to the plan are expected. There were no charges incurred in the three month period ended February 28, 2015. For the six months ended February 28, 2015, the Company incurred pre-tax charges of $17 million, which were primarily related to lease termination costs. All charges related to this plan have been recorded within selling, general and administrative expenses. Restructuring costs by segment are as follows (in millions): Retail Pharmacy Three Months Ended February 29, 2016 USA International Pharmaceutical Wholesale Consolidated Real estate costs $ - $ - $ - $ - Asset impairments - - - - Severance and other business transition and exit costs 25 3 - 28 Total restructuring costs $ 25 $ 3 $ - $ 28 Three Months Ended February 28, 2015 Real estate costs $ - $ - $ - $ - Asset impairments - - - - Severance and other business transition and exit costs - - - - Total restructuring costs $ - $ - $ - $ - Retail Pharmacy Six Months Ended February 29, 2016 USA International Pharmaceutical Wholesale Consolidated Real estate costs $ 52 $ - $ - $ 52 Asset impairments 25 - - 25 Severance and other business transition and exit costs 33 8 - 41 Total restructuring costs $ 110 $ 8 $ - $ 118 Six Months Ended February 28, 2015 Real estate costs $ 17 $ - $ - $ 17 Asset impairments - - - - Severance and other business transition and exit costs - - - - Total restructuring costs $ 17 $ - $ - $ 17

Operating Leases

Operating Leases	6 Months Ended
	Feb. 29, 2016
Operating Leases [Abstract]
Operating Leases	Note 4. Operating Leases Initial terms for leased premises in the U.S. are typically 15 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales. The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. During the three and six months ended February 29, 2016, the Company recorded charges of $9 million and $75 million, respectively, for facilities that were closed or relocated under long-term leases, including stores closed through the Company’s restructuring activities. This compares to no charges for the three months ended and $26 million for the six months ended February 28, 2015. Charges are reported in selling, general and administrative expenses on the Consolidated Condensed Statements of Earnings. The changes in reserve for facility closings and related lease termination charges include the following (in millions): Six Month Period Ended February 29, 2016 Twelve Month Period Ended August 31, 2015 Balance – beginning of period $ 446 $ 257 Provision for present value of non-cancellable lease payments on closed facilities 77 231 Assumptions about future sublease income, terminations and changes in interest rates (14 ) (6 ) Interest accretion 12 27 Liability assumed through acquisition of Alliance Boots - 13 Cash payments, net of sublease income (54 ) (76 ) Balance – end of period $ 467 $ 446 The Company remains secondarily liable on 79 leases. The maximum potential undiscounted future payments are $348 million at February 29, 2016. Lease option dates vary, with some extending to 2039.

Equity Method Investments

Equity Method Investments	6 Months Ended
	Feb. 29, 2016
Equity Method Investments [Abstract]
Equity Method Investments	Note 5. Equity Method Investments Equity method investments as of February 29, 2016 and August 31, 2015 were as follows (in millions, except percentages): February 29, 2016 August 31, 2015 Carrying Value Ownership Percentage Carrying Value Ownership Percentage Equity method investments $ 1,217 12% - 50 % $ 1,242 12% - 50 % The Company's principal equity method investments include its investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Corporation Limited, the Company’s pharmaceutical wholesale investments in China; and the equity method investment retained through the sale of a majority interest in Option Care Inc. in fiscal 2015. See Note 20, Subsequent Event for further information. Equity method investments of the Company are recorded within other non-current assets on the Consolidated Condensed Balance Sheets. The Company Summarized Financial Information Summarized financial information for the Company’s equity method investments is as follows: Balance Sheets (in millions) February 29, 2016 (1) August 31, 2015 (1) Current assets $ 5,687 $ 5,015 Noncurrent assets 1,592 1,548 Current liabilities 4,598 3,936 Noncurrent liabilities 876 837 Shareholders’ equity (2) 1,805 1,790 Statements of Earnings (in millions) Three Months Ended Six Months Ended February 29, 2016 (3) February 28, 2015 (3)(4) February 29, 2016 (3) February 28, 2015 (3)(4) Net sales $ 3,286 $ 5,317 $ 6,489 $ 14,978 Gross Profit 374 979 702 3,168 Net Income 26 246 50 743 Share of income from equity method investments 9 109 20 323 (1) Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates. (2) Shareholders’ equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests. (3) Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates. (4) Includes equity method investment in Alliance Boots from Walgreen Co.’s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.

Available-for-Sale Investments

Available-for-Sale Investments	6 Months Ended
	Feb. 29, 2016
Available-for-Sale Investments [Abstract]
Available-for-Sale Investments	Note 6. Available-for-Sale Investments Walgreens, Alliance Boots and AmerisourceBergen Corporation (“AmerisourceBergen”) entered into a Framework Agreement, dated as of March 18, 2013, pursuant to which Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in AmerisourceBergen, including the right, but not the obligation, to purchase up to 19,859,795 shares of AmerisourceBergen common stock in open market transactions. In conjunction with its long-term relationship with AmerisourceBergen, as of February 29, 2016, the Company held 11.5 million shares, approximately 5.6% of AmerisourceBergen’s outstanding common stock, at a total fair value of $993 million. The Company did not acquire any AmerisourceBergen common shares in the three and six month periods ended February 29, 2016. Pursuant to Accounting Standards Codification (“ASC”) Topic 320, Investments – Debt and Equity Securities, the Company, as of February 29, 2016, accounted for its investment in AmerisourceBergen shares as an available-for-sale investment reported at fair value within other non-current assets in the Consolidated Condensed Balance Sheets. As an available-for-sale investment, changes in the fair value are recorded through other comprehensive income. The value of the investment is recorded at the closing price of AmerisourceBergen common stock as of the balance sheet date. See Note 20, Subsequent Event for further information. A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions): February 29, 2016 Amortized cost basis Gross unrealized gains Gross unrealized losses Fair value AmerisourceBergen common stock $ 717 $ 276 $ - $ 993 Other investments 38 - (4 ) 34 Total available-for-sale investments $ 755 $ 276 $ (4 ) $ 1,027 August 31, 2015 Amortized cost basis Gross unrealized gains Gross unrealized losses Fair value AmerisourceBergen common stock $ 717 $ 430 $ - $ 1,147 Other investments 37 - (1 ) 36 Total available-for-sale investments $ 754 $ 430 $ (1 ) $ 1,183 For the three and six month periods ended February 29, 2016, there were $1 million and $3 million, respectively, of available-for-sale securities sold. There were no sales of available-for-sale investments for the three and six month periods ended February 28, 2015. The Company’s other available-for-sale investments are classified within other current assets in the Consolidated Condensed Balance Sheets.

Acquisitions

Acquisitions	6 Months Ended
	Feb. 29, 2016
Acquisitions [Abstract]
Acquisitions	Note 7. Acquisitions Alliance Boots The Second Step Transaction closed on December 31, 2014, resulting in the acquisition by the Company of 55% of the issued and outstanding share capital of Alliance Boots, increasing its interest to 100%. The Company previously accounted for its 45% interest in Alliance Boots as an equity method investment. As a result of the Second Step Transaction, the Company significantly expanded its operations to include pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution businesses in major international markets. As a result of the closing of the Second Step Transaction, the Company increased its interest in WBAD, a global sourcing enterprise between Walgreens and Alliance Boots, to 100%. Because Walgreens held, prior to the Second Step Transaction, a 50% direct interest and an additional indirect interest in WBAD through its 45% ownership of Alliance Boots, the financial results of WBAD were fully consolidated into the Walgreens financial statements with the remaining 27.5% effective interest being recorded as a noncontrolling interest. The acquisition of the 27.5% noncontrolling interest was accounted for as an equity transaction with no gain or loss recorded in the statement of earnings under ASC Topic 805, Business Combinations. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (“AHID”), which is not a member of the Company’s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000. The Company has completed the purchase accounting of the Second Step Transaction. The total purchase price of the Second Step Transaction of $15.9 billion included £3.133 billion in cash (approximately $4.9 billion at the December 31, 2014 spot rate of $1.56 to £1.00) and 144.3 million of the Company’s common shares at a fair value of $11.0 billion (based on the December 30, 2014 closing market price of $76.05). Of the total purchase price, $13.3 billion was allocated to acquire the 55% ownership interest in Alliance Boots and $2.6 billion was allocated to acquire the noncontrolling interest in WBAD. The purchase price attributed to the acquisition of the noncontrolling interest in WBAD was determined based on the relative fair value of Alliance Boots and WBAD, respectively. The impact of the equity transaction is as follows (in millions): Amount Consideration attributable to WBAD $ 2,559 Less: Carrying value of the Company’s pre-existing noncontrolling interest 130 Impact to additional paid in capital $ 2,429 The following table summarizes the consideration paid to acquire the remaining 55% interest in Alliance Boots and the amounts of identified assets acquired and liabilities assumed at the date of the Second Step Transaction (in millions). Consideration paid Cash $ 4,874 Common stock 10,977 Total consideration transferred 15,851 Less: consideration attributed to WBAD (2,559 ) 13,292 Fair value of the investment in Alliance Boots held before the Second Step Transaction 8,149 Total consideration $ 21,441 Identifiable assets acquired and liabilities assumed including noncontrolling interests Cash and cash equivalents $ 413 Accounts receivable 3,799 Inventories 3,713 Other current assets 894 Property, plant and equipment 3,806 Intangible assets 11,691 Other non-current assets 2,217 Trade accounts payable, accrued expenses and other liabilities (7,696 ) Borrowings (9,010 ) Deferred income taxes (2,452 ) Other non-current liabilities (383 ) Noncontrolling interests (412 ) Total identifiable net assets and noncontrolling interests 6,580 Goodwill $ 14,861 As a result of the Company acquiring the remaining 55% interest in Alliance Boots, the Company’s previously held 45% interest was re-measured at fair value, resulting in a gain of $563 million. The gain has been recognized as Gain on previously held equity interest in the Consolidated Statements of Earnings for the fiscal year ended August 31, 2015. The fair value of the previously held equity interest of $8.1 billion in Alliance Boots was determined using the income approach methodology. The fair value for trade names and trademarks was determined using the relief from royalty method of the income approach; pharmacy licenses and customer relationships were determined using the excess earnings method of the income approach; and loyalty card holders were determined using the incremental cash flow method, which is a form of the income approach. Personal property fair values were determined primarily using the indirect cost approach, while real property fair values were determined using the income, market and/or cost approach. The fair value measurements of the previously held equity interest and intangible assets are based on significant inputs not observable in the market, and thus represent Level 3 measurements. The fair value estimates for the previously held equity interest and intangible assets are based on (a) projected discounted cash flows, (b) historical and projected financial information, (c) synergies including cost savings, and (d) attrition rates, as relevant, that market participants would consider when estimating fair values. The identified definite and indefinite lived intangible assets were as follows: Definite-Lived Intangible Assets Weighted-Average Useful Life (in years) Amount (in millions) Customer relationships 12 $ 1,311 Loyalty card holders 20 742 Trade names and trademarks 9 399 Favorable lease interests 7 93 Total $ 2,545 Indefinite-Lived Intangible Assets Amount (in millions) Trade names and trademarks $ 6,657 Pharmacy licenses 2,489 Total $ 9,146 The goodwill of $14.9 billion arising from the Second Step Transaction primarily reflects the expected purchasing synergies, operating efficiencies by benchmarking performance and applying best practices across the Company, consolidation of operations, reductions in selling, general and administrative expenses and combining workforces. Following the completion of the Second Step Transaction, the Company realigned its operations into three reportable segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company determined that the goodwill should be allocated across all segments recognizing that each segment will benefit from the expected synergies. The goodwill allocated to the Retail Pharmacy USA segment of $7.3 billion is comprised of $3.5 billion of synergy benefits allocable to the segment on a source of procurement benefit basis and $3.8 billion determined on a “with-and-without” basis. The source of procurement benefit basis allocates the synergy benefits to the segment whose purchase gave rise to the benefit. The “with-and-without” basis computes the difference between the fair value of the pre-existing business before the combination and its fair value after the combination, and since the pre-existing Walgreens business is now within the Retail Pharmacy USA segment, all of this difference is allocated to this segment. The “with-and-without” computation recognized that if the Second Step Transaction did not happen, then this was likely to negatively impact the existing Walgreens business, which already had a 45% interest in Alliance Boots, as the expected purchasing synergies and other benefits resulting from a full combination would not be fully realized. Of the remaining goodwill, $3.9 billion was allocated to the Retail Pharmacy International segment and $3.7 billion was allocated to the Pharmaceutical Wholesale segment. Substantially all of the goodwill recognized is not expected to be deductible for income tax purposes. The Company incurred legal and other professional services costs related to the Second Step Transaction, which were included in selling, general and administrative expenses, of $87 million in fiscal 2015 ($59 million and $83 million in the three and six months ended February 28, 2015, respectively). No costs related to the Second Step Transaction were incurred in the three and six month periods ended February 29, 2016. The fair value of the assets acquired includes inventory having an estimated fair value of $3.7 billion. This fair value includes a $106 million fair value adjustment to capitalize the estimated profit in acquired finished goods inventory as of the date of the Second Step Transaction, which was expensed to cost of sales over the first inventory turn. The following table presents supplemental unaudited condensed pro forma consolidated information for the three and six months ended February 28, 2015 as if the Second Step Transaction had occurred on September 1, 2014, the first day of the Company’s 2015 fiscal year. The unaudited condensed pro forma information reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair valuation of assets acquired, the impact of acquisition financing, transaction costs and the related income tax effects. The unaudited condensed pro forma information does not include any anticipated synergies that may be achievable subsequent to the date of the Second Step Transaction. The unaudited condensed pro forma information also excludes certain non-recurring items such as transaction related costs. Accordingly, the unaudited condensed pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company’s results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future. Pro forma Three Months Ended February 28, 2015 Pro forma Six Months Ended February 28, 2015 (in millions, except per share amounts) Net sales $ 30,202 $ 59,173 Net earnings 1,253 2,621 Net earnings per common share: Basic $ 1.20 $ 2.51 Diluted 1.19 2.49 Other Acquisitions The aggregate purchase price of all other businesses, net of cash received was $86 million for the six month period ended February 29, 2016. These acquisitions, primarily of an international beauty brand and prescription files, added $19 million to goodwill and $72 million to intangible assets. The remaining fair value relates to immaterial amounts of tangible assets, less liabilities assumed. Operating results of the businesses acquired have been included in the Consolidated Condensed Statements of Earnings from their respective acquisition dates forward. Pro forma results of the Company, assuming all of the other acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Feb. 29, 2016
Goodwill and Other Intangible Assets [Abstract]
Goodwill and Other Intangible Assets	Note 8. Goodwill and Other Intangible Assets Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions): Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Total August 31, 2015 $ 8,940 $ 3,898 $ 3,534 $ 16,372 Acquisitions - 19 - 19 Other (1) - (3 ) 13 10 Currency translation adjustments - (309 ) (296 ) (605 ) February 29, 2016 $ 8,940 $ 3,605 $ 3,251 $ 15,796 (1) Other represents immaterial purchase accounting adjustments for prior year Company acquisitions. The carrying amount and accumulated amortization of intangible assets consist of the following (in millions): February 29, 2016 August 31, 2015 Gross Amortizable Intangible Assets Customer relationships $ 1,293 $ 1,409 Purchased prescription files 904 885 Loyalty card holders 661 730 Trade names and trademarks 678 675 Favorable lease interests 457 440 Non-compete agreements 158 154 Purchasing and payer contracts 95 94 Total gross amortizable intangible assets 4,246 4,387 Accumulated amortization Customer relationships 182 132 Purchased prescription files 536 470 Loyalty card holders 41 41 Trade names and trademarks 114 83 Favorable lease interests 246 207 Non-compete agreements 106 92 Purchasing and payer contracts 68 65 Total accumulated amortization 1,293 1,090 Total amortizable intangible assets, net $ 2,953 $ 3,297 Indefinite Lived Intangible Assets Trade names and trademarks $ 5,947 $ 6,590 Pharmacy licenses 2,222 2,464 Total indefinite lived intangible assets $ 8,169 $ 9,054 Total intangible assets, net $ 11,122 $ 12,351 Amortization expense for intangible assets was $124 million and $216 million for the three and six months ended February 29, 2016, respectively, and $209 million and $276 million for the three and six months ended February 28, 2015, respectively. Estimated annual amortization expense for intangible assets recorded at February 29, 2016 is as follows (in millions): 2016 2017 2018 2019 2020 Estimated annual amortization expense $ 401 $ 358 $ 318 $ 289 $ 254

Short-Term Borrowings and Long-

Short-Term Borrowings and Long-Term Debt	6 Months Ended
	Feb. 29, 2016
Short-Term Borrowings and Long-Term Debt [Abstract]
Short-Term Borrowings and Long-Term Debt	Note 9. Short-Term Borrowings and Long-Term Debt Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted): February 29, 2016 August 31, 2015 Short-Term Borrowings (1) Unsecured variable rate notes due 2016 $ 749 $ 747 Other (2) 303 321 Total short-term borrowings $ 1,052 $ 1,068 Long-Term Debt (1) Unsecured Pound Sterling variable rate term loan due 2019 (3) $ 2,013 $ 2,229 1.750% unsecured notes due 2017 747 746 5.250% unsecured notes due 2019 (4) 253 250 2.700% unsecured notes due 2019 1,244 1,243 2.875% unsecured Pound Sterling notes due 2020 (3) 552 612 3.300% unsecured notes due 2021 1,241 1,241 3.100% unsecured notes due 2022 1,193 1,193 3.800% unsecured notes due 2024 1,986 1,985 3.600% unsecured Pound Sterling notes due 2025 (3) 414 459 2.125% unsecured Euro notes due 2026 (5) 811 836 4.500% unsecured notes due 2034 494 494 4.400% unsecured notes due 2042 492 492 4.800% unsecured notes due 2044 1,492 1,491 Other (6) 42 44 Total long-term debt $ 12,974 $ 13,315 (1) All notes are presented net of unamortized discount and debt issuance costs, where applicable. (2) Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts. (3) Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively. (4) Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures. (5) Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively. (6) Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities. $8.0 Billion Note Issuance On November 18, 2014, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and estimated offering expenses) of $7.9 billion from a public offering of notes with varying maturities and interest rates, the majority of which are fixed rate. The notes are unsecured, unsubordinated debt obligations of and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged . Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $44 million. The fair value of the notes as of February 29, 2016 was $7.9 billion. Fair value for these notes was determined based upon quoted market prices. The following table summarizes each tranche of notes issued: Notes Issued (in millions) Maturity Date Interest Rate Interest Payment Dates $ 750 May 18, 2016 Variable; three month U.S. dollar LIBOR, reset quarterly, plus 45 basis points February 18, May 18, August 18, and November 18; commencing on February 18, 2015 750 November 17, 2017 Fixed 1.750% May 17 and November 17; commencing on May 17, 2015 1,250 November 18, 2019 Fixed 2.700% May 18 and November 18; commencing on May 18, 2015 1,250 November 18, 2021 Fixed 3.300% May 18 and November 18; commencing on May 18, 2015 2,000 November 18, 2024 Fixed 3.800% May 18 and November 18; commencing on May 18, 2015 500 November 18, 2034 Fixed 4.500% May 18 and November 18; commencing on May 18, 2015 1,500 November 18, 2044 Fixed 4.800% May 18 and November 18; commencing on May 18, 2015 $ 8,000 Redemption Option Walgreens Boots Alliance may redeem (a) the notes due 2017, at any time in whole or from time to time in part, (b) the notes due 2019, at any time prior to October 18, 2019 in whole or from time to time prior to October 18, 2019 in part, (c) the notes due 2021, at any time prior to September 18, 2021 in whole or from time to time prior to September 18, 2021 in part, (d) the notes due 2024, at any time prior to August 18, 2024 in whole or from time to time prior to August 18, 2024 in part, (e) the notes due 2034, at any time prior to May 18, 2034 in whole or from time to time prior to May 18, 2034 in part, and (f) the notes due 2044, at any time prior to May 18, 2044 in whole or from time to time prior to May 18, 2044 in part, in each case, at ’s option for the sum of accrued and unpaid interest plus a redemption price equal to the greater of: (1) 100% of the principal amount of the fixed rate notes being redeemed; and (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 15 basis points for the notes due 2017, 15 basis points for the notes due 2019, 20 basis points for the notes due 2021, 20 basis points for the notes due 2024, 20 basis points for the notes due 2034 and 25 basis points for the notes due 2044. In addition, at any time on or after October 18, 2019 with respect to the notes due 2019, September 18, 2021 with respect to the notes due 2021, August 18, 2024 with respect to the notes due 2024, May 18, 2034 with respect to the notes due 2034, or May 18, 2044 with respect to the notes due 2044, may redeem some or all of the applicable series of fixed rate notes at its option, at a redemption price equal to 100% of the principal amount of the applicable fixed rate notes being redeemed, plus accrued and unpaid interest on the fixed rate notes being redeemed to, but excluding, the redemption date. Change in Control If experiences a change of control triggering event, unless has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest. £700 Million and €750 Million Notes Issuance On November 20, 2014, Walgreens Boots Alliance issued three series of debt securities denominated in Euros and Pound Sterling in a public offering, each with varying maturities and interest rates. Interest on all notes is payable annually on November 20, commencing on November 20, 2015. The notes are unsecured, unsubordinated debt obligations of and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $11 million. The fair value of the notes as of February 29, 2016 was $1.8 billion. Fair value for these notes was determined based upon quoted market prices. The following table details each tranche of Euro and Pound Sterling notes issued: Notes Issued (in millions) Maturity Date Interest Rate Euro Notes: € 750 November 20, 2026 Fixed 2.125% Pound Sterling Notes: £ 400 November 20, 2020 Fixed 2.875% 300 November 20, 2025 Fixed 3.600% £ 700 Redemption Option Walgreens Boots Alliance may redeem (a) the Euro notes, at any time prior to August 20, 2026, in whole or, from time to time prior to August 20, 2026, in part, (b) the Pound Sterling notes due 2020, at any time prior to October 20, 2020, in whole or, from time to time prior to October 20, 2020, in part, and (c) the Pound Sterling notes due 2025, at any time prior to August 20, 2025, in whole or, from time to time prior to August 20, 2025, in part, in each case, at Walgreens Boots Alliance’s option for the sum of accrued and unpaid interest plus at a redemption price equal to the greater of: (1) 100% of the principal amount of the notes to be redeemed; and (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on an annual basis at the applicable Comparable Government Bond Rate (as defined in the applicable series of notes), plus 20 basis points for the Euro notes, 20 basis points for the Pound Sterling notes due 2020 and 20 basis points for Pound Sterling the notes due 2025. In addition, at any time on or after August 20, 2026 with respect to the Euro notes, October 20, 2020 with respect to the Pound Sterling notes due 2020, or August 20, 2025 with respect to the Pound Sterling notes due 2025, Walgreens Boots Alliance may redeem some or all of the applicable series of notes at its option at a redemption price equal to 100% of the principal amount of the applicable notes to be redeemed plus, in every case, accrued and unpaid interest on the notes to be redeemed to, but excluding, the redemption date. Change in Control If Walgreens Boots Alliance experiences a change of control triggering event, unless Walgreens Boots Alliance has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, Walgreens Boots Alliance will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest. $4.0 Billion Note Issuance On September 13, 2012, Walgreens obtained net proceeds from a public offering of $4.0 billion of notes with varying maturities and interest rates, the majority of which, at issuance, were fixed rate. The notes are unsecured senior debt obligations and rank equally with all other unsecured and unsubordinated indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. Total issuance costs relating to the notes, including underwriting discounts and fees, were $26 million. On August 10, 2015, the 1.8000% fixed rate notes due September 15, 2017 in the aggregate principal amount of $1.0 billion were redeemed in full. The redemption price was equal to 101.677% of the aggregate principal amount of the notes redeemed, plus accrued interest thereon to, but excluding, the redemption date, and included a $17 million make whole premium, which was recorded as interest expense on the Company’s Consolidated Statements of Earnings. Additionally, the Company repaid the $750 million 1.000% fixed rate notes on their March 13, 2015 maturity date and the $550 million variable rate notes on their March 13, 2014 maturity date. The following table details each tranche of outstanding notes as of February 29, 2016: Notes Issued (in millions) Maturity Date Interest Rate Interest Payment Dates $ 1,200 September 15, 2022 Fixed 3.100% March 15 and September 15; commencing on March 15, 2013 500 September 15, 2042 Fixed 4.400% March 15 and September 15; commencing on March 15, 2013 $ 1,700 The fair value of the notes outstanding as of February 29, 2016 was $1.6 billion. Fair value for these notes was determined based upon quoted market prices. Redemption Option and Change in Control Walgreens may redeem the fixed rate notes at its option, at any time in whole, or from time to time in part, at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes being redeemed; and (b) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 12 basis points for the notes due 2015, 22 basis points for the notes due 2022 and 25 basis points for the notes due 2042. If a change of control triggering event occurs, Walgreens will be required, unless it has exercised its right to redeem the notes, to offer to purchase the notes at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, on the notes repurchased to the date of repurchase. $1.0 Billion Note Issuance On January 13, 2009, Walgreens issued notes totaling $1.0 billion bearing an interest rate of 5.250% paid semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2009. The notes will mature on January 15, 2019. The notes are unsecured senior debt obligations and rank equally with all other unsecured senior indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. The notes are not convertible or exchangeable. Total issuance costs relating to this offering, including underwriting discounts and fees, were $8 million. On August 10, 2015, $750 million aggregate principal amount of the notes were redeemed. The redemption price was equal to 111.734% of the aggregate principal amount of the notes redeemed plus accrued interest thereon to, but excluding, the redemption date; and included a $88 million make whole premium, which was recorded as interest expense on the Company’s Consolidated Statements of Earnings. The partial redemption of the notes resulted in $250 million aggregate principal amount of the notes remaining outstanding. The fair value of the notes outstanding as of February 29, 2016 was $270 million. Fair value for these notes was determined based upon quoted market prices. Redemption Option and Change in Control Walgreens may redeem the notes, at any time in whole or from time to time in part, at its option at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes to be redeemed; or (b) the sum of the present values of the remaining scheduled payments of principal and interest, discounted to the date of redemption on a semiannual basis at the Treasury Rate (as defined in the applicable series of notes), plus 45 basis points, plus accrued interest on the notes to be redeemed to, but excluding, the date of redemption. If a change of control triggering event occurs, unless Walgreens has exercised its option to redeem the notes, it will be required to offer to repurchase the notes at a purchase price equal to 101% of the principal amount of the notes plus accrued and unpaid interest to the date of redemption. Other Borrowings The Company periodically borrows under its commercial paper program and may borrow under it in future periods. There were no commercial paper borrowings outstanding as of February 29, 2016 or February 28, 2015, respectively. The Company had average daily short-term borrowings of $20 million of commercial paper outstanding at a weighted average interest rate of 0.62% for the six month period ended February 29, 2016. We had average daily short-term borrowings of $4 million of commercial paper outstanding at a weighted average interest rate of 0.46% for the six months ended February 28, 2015. 2014 Term Loan Agreement and Revolving Credit Agreement On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a term loan credit agreement (the “Term Loan Agreement”), which provides Walgreens Boots Alliance and Walgreens with the ability to borrow up to £1.45 billion on an unsecured basis. Borrowings under the Term Loan Agreement bear interest at a fluctuating rate per annum equal to the reserve adjusted LIBOR plus an applicable margin based on the Company’s credit ratings. As of February 29, 2016, Walgreens Boots Alliance had borrowed £1.45 billion ($2.0 billion at the February 29, 2016 spot rate of $1.39 to £1) under the Term Loan Agreement. The fair value of the Term Loan Agreement as of February 29, 2016 was $2.0 billion. Fair value of the borrowings under the Term Loan Agreement was determined based upon quoted market prices. On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a five-year unsecured, multicurrency revolving credit agreement (the “Revolving Credit Agreement”), replacing prior Walgreens agreements dated July 20, 2011 and July 23, 2012. The new unsecured revolving credit agreement initially totaled $2.25 billion, of which $375 million was available for the issuance of letters of credit. On December 29, 2014, upon the affirmative vote of the majority of common shares of Walgreens represented and entitled to vote at the Walgreens special meeting of shareholders to approve the issuance of the shares necessary to complete the Second Step Transaction, the available credit increased to $3.0 billion, of which $500 million is available for the issuance of letters of credit. The issuance of letters of credit reduces the aggregate amount otherwise available under the Revolving Credit Agreement for the making of revolving loans. Borrowings under the Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance’s option, the alternate base rate or the reserve adjusted LIBOR, in each case, plus an applicable margin calculated based on the Company’s credit ratings. As of February 29, 2016, there were no borrowings or letters of credit issued pursuant to the Revolving Credit Agreement. Total upfront fees related to the Term Loan Agreement and Revolving Credit Agreement were $14 million. The Company pays a facility fee to the financing banks to keep these lines of credit active. In accordance with the terms of each of the Term Loan Agreement and the Revolving Credit Agreement, Walgreens guaranteed the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of all of Walgreens Boots Alliance’s obligations under the Term Loan Agreement and Revolving Credit Agreement, as applicable until August 10, 2015, when such guarantees automatically terminated, without penalty to Walgreens or Walgreens Boots Alliance, and the obligations of Walgreens thereunder were unconditionally released and discharged. On December 19, 2014, Walgreens Boots Alliance and Walgreens entered into a Revolving Credit Agreement (as amended, the “364-Day Credit Agreement”) with the lenders party thereto. The 364-Day Credit Agreement was a $750 million, 364-day unsecured, multicurrency revolving facility. On July 9, 2015, Walgreens Boots Alliance amended the 364-Day Credit Agreement to remove Walgreens as a borrower thereunder, eliminate Walgreens’ guarantee of all obligations of Walgreens Boots Alliance thereunder The Term Loan Agreement, Revolving Credit Agreement and the 364-Day Revolving Credit Agreement each contain or contained a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants. 2015 Bridge Credit Agreement and Term Loan Credit Agreement On October 27, 2015, the Company entered into an Agreement and Plan of Merger with Rite Aid Corporation (“Rite Aid”) and Victoria Merger Sub, Inc., a wholly-owned subsidiary of the Company (the “Merger Agreement”). In connection with the Merger Agreement, the Company entered into a bridge facility commitment letter (as amended and restated as of November 19, 2015, the “Commitment Letter”), with UBS Securities LLC and UBS AG, Stamford Branch for a $12.8 billion senior unsecured bridge facility. On December 18, 2015, Walgreens Boots Alliance entered into a Bridge Term Loan Credit Agreement with the lenders party thereto and UBS AG, Stamford Branch, as administrative agent (as amended on January 20, 2016, the “Bridge Credit Agreement”) and a Term Loan Credit Agreement with the lenders party thereto and Bank of America, N.A., as administrative agent (as amended on January 20, 2016, the “Term Loan Credit Agreement” and together with the Bridge Credit Agreement, the “2015 Credit Agreements”). The Commitment Letter and the commitments contemplated thereby terminated upon Walgreens Boots Alliance entering into the 2015 Credit Agreements. The Bridge Credit Agreement is a 364-day unsecured bridge term loan facility. The aggregate commitments of all lenders under the Bridge Credit Agreement are equal to $7.8 billion, provided that Walgreens Boots Alliance may increase the commitments under the Bridge Credit Agreement at any time prior to the funding of the loans thereunder by up to $2.0 billion, subject to obtaining commitments from existing lenders and/or new lenders selected by Walgreens Boots Alliance and reasonably acceptable to the administrative agent. Walgreens Boots Alliance can extend up to $3.0 billion of the loans under the Bridge Credit Agreement for an additional 90-day period if desired. As of February 29, 2016, there were no borrowings under the Bridge Credit Agreement. The Term Loan Credit Agreement is a two-tranche unsecured term loan facility, with the first tranche maturing three years after the earlier of the funding date and October 27, 2016, and the second tranche maturing five years after the earlier of the funding date and October 27, 2016. The aggregate commitments of all lenders under the Term Loan Credit Agreement are equal to $5.0 billion. As of February 29, 2016, there were no borrowings under the Term Loan Credit Agreement. Walgreens Boots Alliance will be the borrower under each of the 2015 Credit Agreements. The ability of Walgreens Boots Alliance to request the making of loans under each of the 2015 Credit Agreements is subject to the satisfaction (or waiver) of certain conditions set forth therein and will terminate upon the occurrence of certain events set forth therein. Borrowings under each of the 2015 Credit Agreements will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance’s option, the alternate base rate or the reserve adjusted Eurocurrency rate, in each case, plus an applicable margin calculated based on Walgreens Boots Alliance’s credit ratings. Upfront fees paid to date in connection with the 2015 Credit Agreements totaled $30 million. A maximum of a further $5 million in upfront fees is payable prior to, or at funding, subject to certain conditions. In addition, Walgreens Boots Alliance will also pay to the lenders under each of the 2015 Credit Agreements certain customary fees, including a ticking fee based on the aggregate outstanding commitments of the lenders under the applicable 2015 Credit Agreement starting at 90 days after signing. Each of the 2015 Credit Agreements contains a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants, which restrictive covenants shall not be in effect until the funding of the loans under the applicable 2015 Credit Agreement.

Financial Instruments

Financial Instruments	6 Months Ended
	Feb. 29, 2016
Financial Instruments [Abstract]
Financial Instruments	Note 10. Financial Instruments The Company uses derivative instruments to manage its exposure to interest rate and foreign currency exchange risks. The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of February 29, 2016, excluding warrants which are presented separately in this footnote, were as follows (in millions): Notional (1) Fair Value Location in Consolidated Condensed Balance Sheets Derivatives designated as fair value hedges Interest rate swaps $ 250 $ 5 Other non-current assets Derivatives not designated as hedges Foreign currency forwards 465 1 Other current assets Foreign currency forwards 768 16 Other current liabilities Basis swap 2 1 Other current liabilities (1) Amounts are presented in U.S. dollar equivalents. The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2015, excluding warrants which are presented separately in this footnote, are as follows (in millions): Notional (1) Fair Value Location in Consolidated Condensed Balance Sheets Derivatives designated as fair value hedges Interest rate swaps $ 250 $ 2 Other non-current assets Derivatives not designated as hedges Foreign currency forwards 1,205 34 Other current assets Foreign currency forwards 495 9 Other current liabilities Basis swap 1 - Other current assets (1) Amounts are presented in U.S. dollar equivalents. The Company uses interest rate swaps to manage the interest rate exposure associated with some of its fixed-rate borrowings and designates them as fair value hedges. The Company uses forward starting interest rate swaps to hedge its interest rate exposure of some of its anticipated debt issuances and designates them as cash flow hedges. The Company utilizes foreign currency forward contracts and other foreign currency derivatives to hedge significant committed and highly probable future transactions and cash flows denominated in currencies other than the functional currency of the Company or its subsidiaries. The Company has significant non-US dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk. Fair Value Hedges The Company entered into a series of interest rate swaps, converting $750 million of its 5.250% fixed rate notes to a floating interest rate based on the six month LIBOR in arrears plus a constant spread and an interest rate swap converting $250 million of its 5.250% fixed rate notes to a floating interest rate based on the one-month LIBOR in arrears plus a constant spread. All swap termination dates coincide with the notes maturity date, January 15, 2019. These swaps were designated as fair value hedges. On August 10, 2015, the Company terminated $500 million of the six month LIBOR in arrears swaps and all of the one-month LIBOR in arrears swaps in connection with the repayment of the associated debt as described in Note 9, Short-Term Borrowings and Long-Term Debt The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions): Location in Consolidated Three Months Ended Six Months Ended Condensed Statements of Earnings February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Interest rate swaps Interest expense, net $ (2 ) $ 4 $ (3 ) $ (6 ) Notes Interest expense, net 2 (4 ) 3 6 The changes in fair value of the Company’s debt that was swapped from fixed to variable rate and designated as fair value hedges are included in short-term and long-term debt on the Consolidated Condensed Balance Sheets (see Note 9, Short-Term Borrowings and Long-Term Debt). At February 29, 2016 and August 31, 2015, the cumulative fair value adjustments resulted in an increase in long-term debt of $4 million and $1 million, respectively. No material gains or losses were recorded from ineffectiveness during the three and six months ended February 29, 2016 and February 28, 2015. Derivatives not Designated as Hedges The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of interest rate and foreign currency risks. The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions): Location in Consolidated Three Months Ended Six Months Ended Condensed Statements of Earnings February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Interest rate swaps Interest expense, net $ - $ (1 ) $ - $ (1 ) Foreign currency forwards Selling, general and administrative expenses (23 ) (28 ) (25 ) (28 ) Second Step Transaction foreign currency forwards Other income (expense) - (70 ) - (166 ) Foreign currency forwards Other income (expense) 33 - 33 - Warrants As of February 29, 2016, the Company held (a) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share, exercisable during a six month period beginning in March 2016, (“Warrant 1”), and (b) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share, exercisable during a six month period beginning in March 2017 (“Warrant 2” and together with Warrant 1, the “Warrants”). Warrant 1 was exercised in full on March 18, 2016. See Note 20, Subsequent Event for further information. The Company reports the Warrants at fair value. The fair value and balance sheet presentation of the Warrants was as follows (in millions): Location in Consolidated Condensed Balance Sheets February 29, 2016 August 31, 2015 Asset derivatives not designated as hedges: Warrants Other non-current assets $ 1,546 $ 2,140 The gains and losses due to changes in fair value of the Warrants recognized in earnings were as follows (in millions): Three Months Ended Six Months Ended Location in Consolidated Condensed Statements of Earnings February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Warrants Other income (expense) $ (532 ) $ 559 $ (594 ) $ 849 Derivatives Credit Risk Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty. Derivatives Offsetting The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Feb. 29, 2016
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 11. Fair Value Measurements The Company measures certain assets and liabilities in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels: Level 1 - Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 - Observable inputs other than quoted prices in active markets. Level 3 - Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Assets and liabilities measured at fair value on a recurring basis were as follows (in millions): February 29, 2016 Level 1 Level 2 Level 3 Assets Restricted cash (1) $ 175 $ 175 $ - $ - Money market funds (2) 2,659 2,659 - - Available-for-sale investments (3) 1,027 1,027 - - Interest rate swaps (4) 5 - 5 - Foreign currency forwards (5) 1 - 1 - Warrants (6) 1,546 - 1,546 - Liabilities Basis swaps (5) 1 - 1 - Foreign currency forwards (5) 16 - 16 - August 31, 2015 Level 1 Level 2 Level 3 Assets Restricted cash (1) $ 184 $ 184 $ - $ - Money market funds (2) 2,043 2,043 - - Available-for-sale investments (3) 1,183 1,183 - - Interest rate swaps (4) 2 - 2 - Foreign currency forwards (5) 34 - 34 - Warrants (6) 2,140 - 2,140 - Liabilities Foreign currency forwards (5) 9 - 9 - (1) Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations. (2) Money market funds are valued at the closing price reported by the fund sponsor. (3) Fair values of quoted investments are based on current bid prices as of the balance sheet dates. See Note 6, Available-for-Sale Investments for additional information. (4) The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information. (5) The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. (6) Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen’s common stock; AmerisourceBergen’s common stock price at the valuation date; AmerisourceBergen’s equity volatility; the number of shares of AmerisourceBergen’s common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the Warrants. There were no transfers between levels for the three and six month periods ended February 29, 2016 and February 28, 2015, respectively. The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the consolidated financial statements. Unless otherwise noted, the fair value for all notes was determined based upon quoted market prices and therefore categorized as Level 1. See Note 9, Short-Term Borrowings and Long-Term Debt for further information. The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Feb. 29, 2016
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, arising in the normal course of the Company’s business, including the matters described below. Legal proceedings, in general, and securities and class action litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit, and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid. On a quarterly basis, the Company assesses its liabilities and contingencies for outstanding legal proceedings and reserves are established on a case-by-case basis for those legal claims for which management concludes that it is probable that a loss will be incurred and that the amount of such loss can be reasonably estimated. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. With respect to litigation and other legal proceedings where the Company has determined that a loss is reasonably possible, the Company is unable to estimate the amount or range of reasonably possible loss in excess of amounts reserved due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company’s assessments are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause the Company to change those estimates and assumptions. Therefore, it is possible that an unfavorable resolution of one or more pending litigation or other contingencies could have a material adverse effect on the Company’s consolidated financial statements in a future fiscal period. Management’s assessment of current litigation and other legal proceedings, including the corresponding accruals, could change because of the discovery of facts with respect to legal actions or other proceedings pending against the Company which are not presently known. Adverse rulings or determinations by judges, juries, governmental authorities or other parties could also result in changes to management’s assessment of current liabilities and contingencies. Accordingly, the ultimate costs of resolving these claims may be substantially higher or lower than the amounts reserved. On December 5 and 12, 2014, putative shareholders filed class actions in federal court in the Northern District of Illinois against the Walgreens Board of Directors, Walgreen Co., and Walgreens Boots Alliance, Inc. arising out of the Company’s definitive proxy statement/prospectus filed with the SEC in connection with the special meeting of Walgreens shareholders on December 29, 2014. The actions asserted claims that the definitive proxy statement/prospectus was false or misleading in various respects. On December 23, 2014, solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, Walgreens entered into a memorandum of understanding with the plaintiffs in both actions, pursuant to which Walgreens made certain supplemental disclosures. The proposed settlement was subject to, among other things, court approval. On July 8, 2015, the Court preliminarily approved the settlement, and on November 20, 2015, the Court entered an order of final approval of the settlement. On December 17, 2015, a purported class member who had objected to the settlement appealed the Court’s order. The appeal was docketed with the United States Court of Appeals for the Seventh Circuit, and is in an early stage. On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co., and Walgreen Co. as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On April 10, 2015, the defendants filed a motion to dismiss. On May 18, 2015, the case was stayed in light of the securities class action that was filed on April 10, 2015, which is described below. On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. On June 16, 2015, the Court entered an order appointing a lead plaintiff. Pursuant to the Court’s order, lead plaintiff filed an amended complaint on August 17, 2015, and defendants moved to dismiss the amended complaint on October 16, 2015. Lead plaintiff filed a response to the motion to dismiss on December 22, 2015, and defendants filed a reply in support of the motion on February 5, 2016. As of February 29, 2016, the Company was aware of ten putative class action lawsuits (the “Rite Aid actions”) filed by purported Rite Aid stockholders against Rite Aid and its board of directors, Walgreens Boots Alliance and for claims arising out of the transactions contemplated by the Merger Agreement (the “Rite Aid Transactions”). Eight of the Rite Aid actions were filed in the Court of Chancery of the State of Delaware (the “Delaware actions”), one Rite Aid action was filed in the State of Pennsylvania in the Court of Common Pleas of Cumberland County (the “Pennsylvania action”), and one Rite Aid action was filed in the United States District Court for the Middle District of Pennsylvania (the “federal action”). The Delaware actions and the Pennsylvania action primarily allege that the Rite Aid board of directors breached its fiduciary duties in connection with the Rite Aid Transactions by, among other things, agreeing to an unfair and inadequate price, agreeing to deal protection devices that preclude other bidders from making successful competing offers for Rite Aid, and failing to disclose all allegedly material information concerning the proposed merger; and also allege that Walgreens Boots Alliance and aided and abetted these alleged breaches of fiduciary duty. The federal action alleges, among other things, that Rite Aid and its board of directors disseminated an allegedly false and misleading proxy statement in connection with the Rite Aid Transactions. The Delaware actions were consolidated, and plaintiffs filed a motion for expedited proceedings and a motion for preliminary injunction seeking to enjoin the Rite Aid shareholder vote on the Rite Aid Transactions. The plaintiffs in the federal action also filed a motion for preliminary injunction seeking to enjoin the same Rite Aid shareholder vote. All such motions were denied, and the Rite Aid shareholders approved the Rite Aid Transactions at a special meeting on February 4, 2016. Each of the Rite Aid actions is still pending.

Retirement Benefits

Retirement Benefits	6 Months Ended
	Feb. 29, 2016
Retirement Benefits [Abstract]
Retirement Benefits	Note 13. Retirement Benefits The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan. The Company uses an August 31 annual measurement date for its pension plans. Defined Benefit Pension Plans (non-US plans) The principal defined benefit pension plan is the Boots Pension Plan, which covers certain employees in the United Kingdom (the “Boots Plan”). The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis. The Company also has two smaller defined benefit pension plans in the United Kingdom, both of which were closed to future accruals effective July 1, 2010. Other defined benefit pension plans include smaller plans in Germany and France. The obligation related to the Company’s pension plans was acquired as a result of the Second Step Transaction . Components of net periodic pension costs for the defined benefit pension plans (in millions): Three Months Ended Six Months Ended February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Service costs $ - $ 1 $ 2 $ 1 Interest costs 77 53 159 53 Expected returns on plan assets (62 ) (43 ) (127 ) (43 ) Settlements - 1 - 1 Total net periodic pension costs $ 15 $ 12 $ 34 $ 12 The Company made cash contributions to its defined benefit pension plans of $9 million for the period ended February 29, 2016, which primarily related to committed funded payments. The Company plans to contribute an additional $66 million to its defined benefit pension plans in fiscal 2016. Defined Contribution Plans The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution, which has historically related to adjusted FIFO earnings before interest and taxes and a portion of which is in the form of a guaranteed match, is determined annually at the discretion of the Walgreens Boots Alliance Board of Directors (or Compensation Committee thereof). The profit-sharing provision was an expense of $53 million and $111 million for the three and six months ended February 29, 2016, respectively, compared to a benefit of $21 million for the three months and expense of $54 million for the six months ended February 28, 2015, respectively. The Company also has a contract based defined contribution arrangement, the Alliance Boots Retirement Savings Plan, to which both the Company and participating employees contribute. The obligation related to the Alliance Boots Retirement Savings Plan was acquired as a result of the Second Step Transaction. The cost recognized in the Consolidated Condensed Statements of Earnings for the three and six month periods ended February 29, 2016 was $34 million and $69 million, respectively compared to $22 million in the prior year three and six month periods. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, such costs for fiscal 2015 prior to the date of the Second Step Transaction were reflected within Equity earnings in Alliance Boots on the Consolidated Condensed Statement of Earnings. Postretirement Healthcare Plan The Company provides certain health insurance benefits to retired U.S. employees who meet eligibility requirements, including age, years of service and date of hire. The costs of these benefits are accrued over the service life of the employee. The Company’s postretirement health benefit plan is not funded. Components of net periodic benefit cost for the postretirement health benefit plan (in millions): Three Months Ended Six Months Ended February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Service cost $ 2 $ 2 $ 5 $ 5 Interest cost 5 4 10 8 Amortization of actuarial loss 5 5 9 10 Amortization of prior service cost (7 ) (6 ) (14 ) (12 ) Total postretirement benefit cost $ 5 $ 5 $ 10 $ 11

Earnings Per Share

Earnings Per Share	6 Months Ended
	Feb. 29, 2016
Earnings Per Share [Abstract]
Earnings Per Share	Note 14. Earnings Per Share The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 3.2 million outstanding options to purchase common shares that were anti-dilutive and excluded from the second quarter earnings per share calculation as of February 29, 2016 compared to 3.4 million as of February 28, 2015. Anti-dilutive shares excluded from the year to date earnings per share calculation were 2.2 million compared to 5.0 million for the periods ending February 29, 2016 and February 28, 2015, respectively.

Depreciation and Amortization

Depreciation and Amortization	6 Months Ended
	Feb. 29, 2016
Depreciation and Amortization [Abstract]
Depreciation and Amortization	Note 15. Depreciation and Amortization The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions): Three Months Ended Six Months Ended February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Depreciation expense $ 346 $ 311 $ 644 $ 567 Intangible asset and other amortization 96 196 180 259 Total depreciation and amortization expense $ 442 $ 507 $ 824 $ 826 The depreciation and amortization expense presented for 2015 include Alliance Boots costs for the period from December 31, 2014 through February 28, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, depreciation and amortization expense were included for fiscal 2015 prior to the date of the Second Step Transaction within Equity earnings in Alliance Boots.

Supplemental Cash Flow Disclosu

Supplemental Cash Flow Disclosures	6 Months Ended
	Feb. 29, 2016
Supplemental Cash Flow Disclosures [Abstract]
Supplemental Cash Flow Disclosures	Note 16. Supplemental Cash Flow Disclosures Cash interest paid was $302 million and $90 million in the six months ended February 29, 2016 and February 28, 2015, respectively. Cash paid for income taxes was $481 million and $553 million in the six months ended February 29, 2016 and February 28, 2015, respectively.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Feb. 29, 2016
Accumulated Other Comprehensive Income (Loss) [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 17. Accumulated Other Comprehensive Income (Loss) The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and six months ended February 29, 2016 and February 28, 2015 (in millions): Pension/Post- retirement Obligations Unrecognized Gain (Loss) on Available-for-Sale Investments Unrealized Gain (Loss) on Cash Flow Hedges Currency Translation Adjustments Total Balance at November 30, 2015 $ 32 $ 260 $ (39 ) $ (911 ) $ (658 ) Other comprehensive income (loss) before reclassification adjustments (4 ) (139 ) - (1,121 ) (1,264 ) Amounts reclassified from accumulated OCI - - 2 - 2 Tax benefit (provision) 2 51 (1 ) - 52 Net other comprehensive income (loss) (2 ) (88 ) 1 (1,121 ) (1,210 ) Balance at February 29, 2016 $ 30 $ 172 $ (38 ) $ (2,032 ) $ (1,868 ) Pension/Post- retirement Obligations Unrecognized Gain (Loss) on Available-for-Sale Investments Unrealized Gain (Loss) on Cash Flow Hedges Currency Translation Adjustments Total Balance at August 31, 2015 $ 29 $ 259 $ (40 ) $ (462 ) $ (214 ) Other comprehensive income (loss) before reclassification adjustments (1 ) (144 ) - (1,570 ) (1,715 ) Amounts reclassified from accumulated OCI - - 3 - 3 Tax benefit (provision) 2 57 (1 ) - 58 Net other comprehensive income (loss) 1 (87 ) 2 (1,570 ) (1,654 ) Balance at February 29, 2016 $ 30 $ 172 $ (38 ) $ (2,032 ) $ (1,868 ) Pension/Post- retirement Obligations Unrecognized Gain (Loss) on Available-for-Sale Investments Unrealized Gain (Loss) on Cash Flow Hedges Share of Alliance Boots OCI Cumulative Translation Adjustments Total Balance at November 30, 2014 $ 14 $ 206 $ (39 ) $ (92 ) $ (35 ) $ 54 Other comprehensive income (loss) before reclassification adjustments (8 ) 140 2 (89 ) (358 ) (313 ) Amounts reclassified from accumulated OCI - - (1 ) 230 80 309 Tax benefit (provision) - (50 ) (1 ) (49 ) (18 ) (118 ) Net other comprehensive income (loss) $ (8 ) $ 90 $ - $ 92 $ (296 ) $ (122 ) Balance at February 28, 2015 $ 6 $ 296 $ (39 ) $ - $ (331 ) $ (68 ) Pension/Post- retirement Obligations Unrecognized Gain (Loss) on Available-for-Sale Investments Unrealized Gain (Loss) on Cash Flow Hedges Share of Alliance Boots OCI Cumulative Translation Adjustments Total Balance at August 31, 2014 $ 15 $ 107 $ (27 ) $ (113 ) $ 154 $ 136 Other comprehensive income (loss) before reclassification adjustments (10 ) 297 (18 ) (57 ) (648 ) (436 ) Amounts reclassified from accumulated OCI - - (1 ) 230 80 309 Tax benefit (provision) 1 (108 ) 7 (60 ) 83 (77 ) Net other comprehensive income (loss) $ (9 ) $ 189 $ (12 ) $ 113 $ (485 ) $ (204 ) Balance at February 28, 2015 $ 6 $ 296 $ (39 ) $ - $ (331 ) $ (68 )

Segment Reporting

Segment Reporting	6 Months Ended
	Feb. 29, 2016
Segment Reporting [Abstract]
Segment Reporting	Note 18. Segment Reporting The Company has three reportable segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments, which have been aggregated as described below. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included. · The Retail Pharmacy USA segment consists of the legacy Walgreens business, which includes the operation of retail drugstores and convenient care clinics and the provision of specialty pharmacy services. Revenues for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods. · The Retail Pharmacy International segment consists primarily of the legacy Alliance Boots pharmacy-led health and beauty stores, optical practices, and related contract manufacturing operations. Stores are located in the United Kingdom, Mexico, Chile, Thailand, Norway, the Republic of Ireland, The Netherlands and Lithuania. Revenues for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products. · The Pharmaceutical Wholesale segment consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses. Wholesale operations are located in France, the United Kingdom, Germany, Turkey, Spain, Russia, The Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Revenues for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers. The results of operations for each reportable segment include synergy benefits, including WBAD operations and an allocation of corporate-related overhead costs. The “Eliminations and Unallocated Items” column contains items not allocable to the reportable segments, as the information is not utilized by the chief operating decision maker to assess segment performance and allocate resources. The segment information reflects the operating results of the Company’s business segments. The Company began recording revenue and expense transactions using the new segments effective January 1, 2015. Beginning January 1, 2015, synergy benefits including WBAD operations have been allocated to the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale segments on a source of procurement benefit basis. Under this method, the synergy benefits are allocated to the segment whose purchase gave rise to the benefit. A synergy arising on the purchase of an item for use in an entity in the Retail Pharmacy USA segment is recognized in the Retail Pharmacy USA segment and similarly for the Retail Pharmacy International and Pharmaceutical Wholesale segments. Procurement service income related to third parties is recognized in the Pharmaceutical Wholesale segment. Corporate costs have been allocated to segments based on their respective gross profit. Our Retail Pharmacy International and Pharmaceutical Wholesale segments were acquired as part of the Second Step Transaction in which we acquired the 55% of Alliance Boots that we did not already own on December 31, 2014. The Company has determined that it is impracticable to restate segment information for periods prior the completion of the Second Step Transaction, as well as to provide disclosures for such periods under both the old basis and new basis of reporting for certain items. Specifically, WBAD operations prior to December 31, 2014 were recorded in the Retail Pharmacy USA segment and have not been restated, as the Company believes it is impracticable to separate the information to the individual reportable segments. Equity earnings from Alliance Boots prior to the completion of the Second Step Transaction has been recorded within the Retail Pharmacy USA segment. The equity earnings of the 45% interest in Alliance Boots have not been separated into the Retail Pharmacy International and Pharmaceutical Wholesale segments for the prior period, as the Company believes it is impracticable. Accordingly, only two months of results (January and February 2015) have been reported for these segments for the three and six months ended February 28, 2015. The following table reflects results of operations of the Company’s reportable segments (in millions): Retail Pharmacy USA International Pharmaceutical Wholesale Eliminations and Unallocated Items Consolidated Three Months Ended February 29, 2016 Sales to external customers $ 21,500 $ 3,627 $ 5,057 $ - $ 30,184 Intersegment sales - 62 570 (632 ) - Total Sales 21,500 3,689 5,627 (632 ) 30,184 Adjusted Operating Income $ 1,632 $ 335 $ 155 $ (2 ) $ 2,120 Three Months Ended February 28, 2015 Sales to external customers $ 21,048 $ 2,017 $ 3,508 $ - $ 26,573 Intersegment sales - 30 357 (387 ) - Total Sales 21,048 2,047 3,865 (387 ) 26,573 Adjusted Operating Income $ 1,598 $ 125 $ 121 $ (4 ) $ 1,840 Retail Pharmacy USA International Pharmaceutical Wholesale Eliminations and Unallocated Items Consolidated Six Months Ended February 29, 2016 Sales to external customers $ 41,870 $ 7,086 $ 10,261 $ - $ 59,217 Intersegment sales - 134 1,162 (1,296 ) - Total Sales 41,870 7,220 11,423 (1,296 ) 59,217 Adjusted Operating Income $ 2,875 $ 650 $ 321 $ (7 ) $ 3,839 Six Months Ended February 28, 2015 Sales to external customers $ 40,602 $ 2,017 $ 3,508 $ - $ 46,127 Intersegment sales - 30 357 (387 ) - Total Sales 40,602 2,047 3,865 (387 ) 46,127 Adjusted Operating Income $ 2,716 $ 125 $ 121 $ (4 ) $ 2,958 The following table reconciles adjusted operating income to operating income (in millions): Retail Pharmacy USA International Pharmaceutical Wholesale Eliminations and Unallocated Items Consolidated Three Months Ended February 29, 2016 Adjusted Operating Income $ 1, 632 $ 335 $ 155 $ (2 ) $ 2,120 Acquisition-related amortization (101 ) Cost transformation (28 ) LIFO provision (68 ) Acquisition-related costs (33 ) Asset impairment (30 ) Operating Income $ 1,860 Three Months Ended February 28, 2015 Adjusted Operating Income $ 1,598 $ 125 $ 121 $ (4 ) $ 1,840 (Decrease) increase in fair market value of warrants (6 ) Acquisition-related amortization (217 ) LIFO provision (55 ) Acquisition-related costs (59 ) Asset impairment (110 ) Store closures and other optimization costs (16 ) Operating Income $ 1,377 Retail Pharmacy USA International Pharmaceutical Wholesale Eliminations and Unallocated Items Consolidated Six Months Ended February 29, 2016 Adjusted Operating Income $ 2,875 $ 650 $ 321 $ (7 ) $ 3,839 Acquisition-related amortization (182 ) Cost transformation (118 ) LIFO provision (114 ) Acquisition-related costs (67 ) Asset impairment (30 ) Operating Income $ 3,328 Six Months Ended February 28, 2015 Adjusted Operating Income $ 2,716 $ 125 $ 121 $ (4 ) $ 2,958 (Decrease) increase in fair market value of warrants 123 Acquisition-related amortization (306 ) LIFO provision (107 ) Acquisition-related costs (83 ) Asset impairment (110 ) Store closures and other optimization costs (44 ) Operating Income $ 2,431

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Feb. 29, 2016
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	Note 19. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which supersedes Topic 840, Leases. This ASU increases the transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed. At the lease commencement date, lessee recognizes a lease liability and right-of-use asset, which is initially measured at the present value of future lease payments. There are two approaches for amortizing the right-of use asset. Under the finance lease approach, interest on the lease liability is recognized separately from amortization of the right-of-use asset. Repayments of the principal portion of the lease liability will be classified as financing activities and payments of interest on the lease liability and variable lease payments will be classified as operating activities in the statement of cash flows. Under the operating lease approach, the cost of the lease is calculated on a straight-line basis over the life of the lease term. All cash payments are classified as operating activities in the statement of cash flows. For sale and leaseback transactions, in order for a sale to occur, the transfer of the asset must meet all criteria in Topic 606. If there is no sale for the seller-lessee, the buyer-lessor does not account for a purchase. Any consideration paid for the asset is accounted for as a financing transaction. For transactions previously accounted for as a sale and leaseback, the transition guidance in Topic 842 does not require an entity to assess whether the transaction would have qualified as a sale and a leaseback in accordance with Topic 842. Additionally, gains recorded under sale and leaseback transactions are recognized at the transaction date and no longer deferred over the lease term. This ASU is effective for annual periods beginning after December 15, 2018 (fiscal 2020). In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach which includes a number of optional practical expedients that entities may elect to apply. For a description of the Company’s lease obligations, please refer to the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2015. The Company has begun evaluating and planning for the adoption and implementation of this ASU, including assessing the overall impact. This ASU will have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is being evaluated. The impact of this ASU is non-cash in nature and will not affect the Company’s cash position. In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10). This ASU requires equity investments (except those under the equity method of accounting or those that result in the consolidation of an investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This simplifies the impairment assessment of equity investments previous held at cost. Separate presentation of financial assets and liabilities by measurement category is required. This ASU is effective prospectively for annual periods beginning after December 15, 2017 (fiscal 2019). Early application is not permitted. The Company is evaluating the effect of adopting this new accounting guidance. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). This ASU simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in a classified statement of financial position. This ASU may be applied either prospectively to all deferred tax assets and liabilities, or retrospectively to all periods presented for annual periods beginning after December 16, 2016 and interim periods thereafter (fiscal 2018), with early adoption permitted, and may require additional disclosure based on the application method selected. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company’s financial position. In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805). This ASU simplifies the accounting for adjustments made to provisional amounts recognized in a business combination by eliminating the requirements to retrospectively account for those adjustments. This guidance applies to all entities that have reported provisional amounts for items in a business combination for which the accounting is incomplete by the end of the reporting period in which the combination occurs and during the measurement period having an adjustment to provisional amounts recognized. This ASU is effective prospectively for annual periods beginning after December 31, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. The Company adopted this ASU on March 1, 2016. The adoption of this ASU did not have a material impact on the Company’s results of operations, cash flows or financial position. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), an update to ASU 2014-09. This ASU amends ASU 2014-09 to defer the effective date by one year for annual reporting periods beginning after December 15, 2017 (fiscal 2019). This ASU removes inconsistencies, complexities and allows transparency and comparability of revenue transactions across entities, industries, jurisdictions and capital markets by providing a single comprehensive principles-based model with additional disclosures regarding uncertainties. The principles-based revenue recognition model has a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Early adoption is permitted for annual reporting periods beginning after December 15, 2016 (fiscal 2018). In transition, the ASU may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance including the transition method. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). This ASU simplifies current accounting treatments by requiring entities to measure most inventories at “the lower of cost and net realizable value” rather than using lower of cost or market. This guidance does not apply to inventories measured using last-in, first-out method or the retail inventory method. This ASU is effective prospectively for annual periods beginning after December 15, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. Upon transition, entities must disclose the accounting change. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company’s results of operations, cash flows or financial position.

Subsequent Event

Subsequent Event	6 Months Ended
	Feb. 29, 2016
Subsequent Event [Abstract]
Subsequent Event	Note 20. Subsequent Event On March 18, 2016, the Company exercised Warrant 1 (described in Note 10, Financial Instruments) in full, resulting in the acquisition from AmerisourceBergen of 22,696,912 shares of AmerisourceBergen common stock for an aggregate exercise price payment of $1.17 billion. The transaction was funded using existing cash on hand. Following the exercise of Warrant 1, the Company owned 34,157,955 outstanding AmerisourceBergen common shares representing approximately 15.2% of the outstanding AmerisourceBergen common stock (based on shares outstanding as of March 16, 2016 adjusted to give effect to the exercise of Warrant 1, as reported by AmerisourceBergen in its Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2016). The Company continues to hold Warrant 2, which the Company has the right to exercise beginning in March 2017. Effective March 18, 2016, the Company accounts for its investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings attributable to its investment being classified within the operating income of the Company’s Pharmaceutical Wholesale segment.

Accounting Policies (Policies)

Accounting Policies (Policies)	6 Months Ended
	Feb. 29, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated condensed financial statements of Walgreens Boots Alliance included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The consolidated condensed financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned entities in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated. The Consolidated Condensed Balance Sheet as of February 29, 2016, the Consolidated Condensed Statements of Equity for the six-month period ended February 29, 2016, and the Consolidated Condensed Statements of Earnings, the Consolidated Condensed Statements of Comprehensive Income and the Consolidated Condensed Statements of Cash Flows for the three month and six month periods ended February 29, 2016 and February 28, 2015, have not been audited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015. In the opinion of the Company, the unaudited consolidated condensed financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company’s operations, net earnings for any interim period may not be comparable to the same interim period in previous years or indicative of net earnings for the full fiscal year. In addition, with respect to the Company’s Retail Pharmacy USA segment, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a “generic conversion.” In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on Retail Pharmacy USA segment’s sales, gross profit margins and gross profit dollars. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. For a discussion of the Company’s significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Feb. 29, 2016
Restructuring [Abstract]
Restructuring Costs by Segment	Restructuring costs by segment are as follows (in millions): Retail Pharmacy Three Months Ended February 29, 2016 USA International Pharmaceutical Wholesale Consolidated Real estate costs $ - $ - $ - $ - Asset impairments - - - - Severance and other business transition and exit costs 25 3 - 28 Total restructuring costs $ 25 $ 3 $ - $ 28 Three Months Ended February 28, 2015 Real estate costs $ - $ - $ - $ - Asset impairments - - - - Severance and other business transition and exit costs - - - - Total restructuring costs $ - $ - $ - $ - Retail Pharmacy Six Months Ended February 29, 2016 USA International Pharmaceutical Wholesale Consolidated Real estate costs $ 52 $ - $ - $ 52 Asset impairments 25 - - 25 Severance and other business transition and exit costs 33 8 - 41 Total restructuring costs $ 110 $ 8 $ - $ 118 Six Months Ended February 28, 2015 Real estate costs $ 17 $ - $ - $ 17 Asset impairments - - - - Severance and other business transition and exit costs - - - - Total restructuring costs $ 17 $ - $ - $ 17

Operating Leases (Tables)

Operating Leases (Tables)	6 Months Ended
	Feb. 29, 2016
Operating Leases [Abstract]
Reserve for Facility Closings and Related Lease Termination Charges	The changes in reserve for facility closings and related lease termination charges include the following (in millions): Six Month Period Ended February 29, 2016 Twelve Month Period Ended August 31, 2015 Balance – beginning of period $ 446 $ 257 Provision for present value of non-cancellable lease payments on closed facilities 77 231 Assumptions about future sublease income, terminations and changes in interest rates (14 ) (6 ) Interest accretion 12 27 Liability assumed through acquisition of Alliance Boots - 13 Cash payments, net of sublease income (54 ) (76 ) Balance – end of period $ 467 $ 446

Equity Method Investments (Tabl

Equity Method Investments (Tables)	6 Months Ended
	Feb. 29, 2016
Equity Method Investments [Abstract]
Equity Method Investments	Equity method investments as of February 29, 2016 and August 31, 2015 were as follows (in millions, except percentages): February 29, 2016 August 31, 2015 Carrying Value Ownership Percentage Carrying Value Ownership Percentage Equity method investments $ 1,217 12% - 50 % $ 1,242 12% - 50 %
Summarized Financial Information of Equity Method Investees	Summarized financial information for the Company’s equity method investments is as follows: Balance Sheets (in millions) February 29, 2016 (1) August 31, 2015 (1) Current assets $ 5,687 $ 5,015 Noncurrent assets 1,592 1,548 Current liabilities 4,598 3,936 Noncurrent liabilities 876 837 Shareholders’ equity (2) 1,805 1,790 Statements of Earnings (in millions) Three Months Ended Six Months Ended February 29, 2016 (3) February 28, 2015 (3)(4) February 29, 2016 (3) February 28, 2015 (3)(4) Net sales $ 3,286 $ 5,317 $ 6,489 $ 14,978 Gross Profit 374 979 702 3,168 Net Income 26 246 50 743 Share of income from equity method investments 9 109 20 323 (1) Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates. (2) Shareholders’ equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests. (3) Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates. (4) Includes equity method investment in Alliance Boots from Walgreen Co.’s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.

Available-for-Sale Investments

Available-for-Sale Investments (Tables)	6 Months Ended
	Feb. 29, 2016
Available-for-Sale Investments [Abstract]
Summary of Cost and Fair Value of Available-for-Sale Securities	A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions): February 29, 2016 Amortized cost basis Gross unrealized gains Gross unrealized losses Fair value AmerisourceBergen common stock $ 717 $ 276 $ - $ 993 Other investments 38 - (4 ) 34 Total available-for-sale investments $ 755 $ 276 $ (4 ) $ 1,027 August 31, 2015 Amortized cost basis Gross unrealized gains Gross unrealized losses Fair value AmerisourceBergen common stock $ 717 $ 430 $ - $ 1,147 Other investments 37 - (1 ) 36 Total available-for-sale investments $ 754 $ 430 $ (1 ) $ 1,183

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Feb. 29, 2016
Acquisitions [Abstract]
Schedule of Impact of Equity Transaction	The impact of the equity transaction is as follows (in millions): Amount Consideration attributable to WBAD $ 2,559 Less: Carrying value of the Company’s pre-existing noncontrolling interest 130 Impact to additional paid in capital $ 2,429
Schedule of Business Acquisition Total Consideration Paid	Consideration paid Cash $ 4,874 Common stock 10,977 Total consideration transferred 15,851 Less: consideration attributed to WBAD (2,559 ) 13,292 Fair value of the investment in Alliance Boots held before the Second Step Transaction 8,149 Total consideration $ 21,441
Schedule of Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests	Identifiable assets acquired and liabilities assumed including noncontrolling interests Cash and cash equivalents $ 413 Accounts receivable 3,799 Inventories 3,713 Other current assets 894 Property, plant and equipment 3,806 Intangible assets 11,691 Other non-current assets 2,217 Trade accounts payable, accrued expenses and other liabilities (7,696 ) Borrowings (9,010 ) Deferred income taxes (2,452 ) Other non-current liabilities (383 ) Noncontrolling interests (412 ) Total identifiable net assets and noncontrolling interests 6,580 Goodwill $ 14,861
Schedule of Identified Definite and Indefinite Lived Intangible Assets	The identified definite and indefinite lived intangible assets were as follows: Definite-Lived Intangible Assets Weighted-Average Useful Life (in years) Amount (in millions) Customer relationships 12 $ 1,311 Loyalty card holders 20 742 Trade names and trademarks 9 399 Favorable lease interests 7 93 Total $ 2,545 Indefinite-Lived Intangible Assets Amount (in millions) Trade names and trademarks $ 6,657 Pharmacy licenses 2,489 Total $ 9,146
Schedule of Unaudited Pro Forma Results Prepared for Comparative Purposes	Accordingly, the unaudited condensed pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company’s results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future. Pro forma Three Months Ended February 28, 2015 Pro forma Six Months Ended February 28, 2015 (in millions, except per share amounts) Net sales $ 30,202 $ 59,173 Net earnings 1,253 2,621 Net earnings per common share: Basic $ 1.20 $ 2.51 Diluted 1.19 2.49

Goodwill and Other Intangible35

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Feb. 29, 2016
Goodwill and Other Intangible Assets [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions): Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Total August 31, 2015 $ 8,940 $ 3,898 $ 3,534 $ 16,372 Acquisitions - 19 - 19 Other (1) - (3 ) 13 10 Currency translation adjustments - (309 ) (296 ) (605 ) February 29, 2016 $ 8,940 $ 3,605 $ 3,251 $ 15,796 (1) Other represents immaterial purchase accounting adjustments for prior year Company acquisitions.
Schedule of Finite-Lived Intangible Assets by Major Class	The carrying amount and accumulated amortization of intangible assets consist of the following (in millions): February 29, 2016 August 31, 2015 Gross Amortizable Intangible Assets Customer relationships $ 1,293 $ 1,409 Purchased prescription files 904 885 Loyalty card holders 661 730 Trade names and trademarks 678 675 Favorable lease interests 457 440 Non-compete agreements 158 154 Purchasing and payer contracts 95 94 Total gross amortizable intangible assets 4,246 4,387 Accumulated amortization Customer relationships 182 132 Purchased prescription files 536 470 Loyalty card holders 41 41 Trade names and trademarks 114 83 Favorable lease interests 246 207 Non-compete agreements 106 92 Purchasing and payer contracts 68 65 Total accumulated amortization 1,293 1,090 Total amortizable intangible assets, net $ 2,953 $ 3,297 Indefinite Lived Intangible Assets Trade names and trademarks $ 5,947 $ 6,590 Pharmacy licenses 2,222 2,464 Total indefinite lived intangible assets $ 8,169 $ 9,054 Total intangible assets, net $ 11,122 $ 12,351
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated annual amortization expense for intangible assets recorded at February 29, 2016 is as follows (in millions): 2016 2017 2018 2019 2020 Estimated annual amortization expense $ 401 $ 358 $ 318 $ 289 $ 254

Short-Term Borrowings and Lon36

Short-Term Borrowings and Long-Term Debt (Tables)	6 Months Ended
	Feb. 29, 2016
Short-Term Borrowings and Long-Term Debt [Abstract]
Short-Term Borrowings	Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted): February 29, 2016 August 31, 2015 Short-Term Borrowings (1) Unsecured variable rate notes due 2016 $ 749 $ 747 Other (2) 303 321 Total short-term borrowings $ 1,052 $ 1,068 (1) All notes are presented net of unamortized discount and debt issuance costs, where applicable. (2) Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts. (3) Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively. (4) Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures. (5) Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively. (6) Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
Long-Term Debt	Long-Term Debt (1) Unsecured Pound Sterling variable rate term loan due 2019 (3) $ 2,013 $ 2,229 1.750% unsecured notes due 2017 747 746 5.250% unsecured notes due 2019 (4) 253 250 2.700% unsecured notes due 2019 1,244 1,243 2.875% unsecured Pound Sterling notes due 2020 (3) 552 612 3.300% unsecured notes due 2021 1,241 1,241 3.100% unsecured notes due 2022 1,193 1,193 3.800% unsecured notes due 2024 1,986 1,985 3.600% unsecured Pound Sterling notes due 2025 (3) 414 459 2.125% unsecured Euro notes due 2026 (5) 811 836 4.500% unsecured notes due 2034 494 494 4.400% unsecured notes due 2042 492 492 4.800% unsecured notes due 2044 1,492 1,491 Other (6) 42 44 Total long-term debt $ 12,974 $ 13,315 (1) All notes are presented net of unamortized discount and debt issuance costs, where applicable. (2) Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts. (3) Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively. (4) Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures. (5) Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively. (6) Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
Total $8.0 Billion Debt Issuance [Member]
Debt Instrument [Line Items]
Details of Each Tranche of Notes Issued	The following table summarizes each tranche of notes issued: Notes Issued (in millions) Maturity Date Interest Rate Interest Payment Dates $ 750 May 18, 2016 Variable; three month U.S. dollar LIBOR, reset quarterly, plus 45 basis points February 18, May 18, August 18, and November 18; commencing on February 18, 2015 750 November 17, 2017 Fixed 1.750% May 17 and November 17; commencing on May 17, 2015 1,250 November 18, 2019 Fixed 2.700% May 18 and November 18; commencing on May 18, 2015 1,250 November 18, 2021 Fixed 3.300% May 18 and November 18; commencing on May 18, 2015 2,000 November 18, 2024 Fixed 3.800% May 18 and November 18; commencing on May 18, 2015 500 November 18, 2034 Fixed 4.500% May 18 and November 18; commencing on May 18, 2015 1,500 November 18, 2044 Fixed 4.800% May 18 and November 18; commencing on May 18, 2015 $ 8,000
Euro and Pound Sterling Notes [Member]
Debt Instrument [Line Items]
Details of Each Tranche of Notes Issued	The following table details each tranche of Euro and Pound Sterling notes issued: Notes Issued (in millions) Maturity Date Interest Rate Euro Notes: € 750 November 20, 2026 Fixed 2.125% Pound Sterling Notes: £ 400 November 20, 2020 Fixed 2.875% 300 November 20, 2025 Fixed 3.600% £ 700
Total $4.0 Billion Debt Issuance [Member]
Debt Instrument [Line Items]
Details of Each Tranche of Notes Issued	The following table details each tranche of outstanding notes as of February 29, 2016: Notes Issued (in millions) Maturity Date Interest Rate Interest Payment Dates $ 1,200 September 15, 2022 Fixed 3.100% March 15 and September 15; commencing on March 15, 2013 500 September 15, 2042 Fixed 4.400% March 15 and September 15; commencing on March 15, 2013 $ 1,700

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Feb. 29, 2016
Financial Instruments [Abstract]
Notional Amounts of Derivative Instruments Outstanding	The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of February 29, 2016, excluding warrants which are presented separately in this footnote, were as follows (in millions): Notional (1) Fair Value Location in Consolidated Condensed Balance Sheets Derivatives designated as fair value hedges Interest rate swaps $ 250 $ 5 Other non-current assets Derivatives not designated as hedges Foreign currency forwards 465 1 Other current assets Foreign currency forwards 768 16 Other current liabilities Basis swap 2 1 Other current liabilities (1) Amounts are presented in U.S. dollar equivalents. The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2015, excluding warrants which are presented separately in this footnote, are as follows (in millions): Notional (1) Fair Value Location in Consolidated Condensed Balance Sheets Derivatives designated as fair value hedges Interest rate swaps $ 250 $ 2 Other non-current assets Derivatives not designated as hedges Foreign currency forwards 1,205 34 Other current assets Foreign currency forwards 495 9 Other current liabilities Basis swap 1 - Other current assets (1) Amounts are presented in U.S. dollar equivalents.
Schedule of Derivative Assets at Fair Value	The Company reports the Warrants at fair value. The fair value and balance sheet presentation of the Warrants was as follows (in millions): Location in Consolidated Condensed Balance Sheets February 29, 2016 August 31, 2015 Asset derivatives not designated as hedges: Warrants Other non-current assets $ 1,546 $ 2,140
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gains and Losses due to Changes in Fair Value Recognized in Earnings	The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions): Location in Consolidated Three Months Ended Six Months Ended Condensed Statements of Earnings February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Interest rate swaps Interest expense, net $ (2 ) $ 4 $ (3 ) $ (6 ) Notes Interest expense, net 2 (4 ) 3 6
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gains and Losses due to Changes in Fair Value Recognized in Earnings	The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions): Location in Consolidated Three Months Ended Six Months Ended Condensed Statements of Earnings February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Interest rate swaps Interest expense, net $ - $ (1 ) $ - $ (1 ) Foreign currency forwards Selling, general and administrative expenses (23 ) (28 ) (25 ) (28 ) Second Step Transaction foreign currency forwards Other income (expense) - (70 ) - (166 ) Foreign currency forwards Other income (expense) 33 - 33 -
Warrant [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gains and Losses due to Changes in Fair Value Recognized in Earnings	The gains and losses due to changes in fair value of the Warrants recognized in earnings were as follows (in millions): Three Months Ended Six Months Ended Location in Consolidated Condensed Statements of Earnings February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Warrants Other income (expense) $ (532 ) $ 559 $ (594 ) $ 849

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Feb. 29, 2016
Fair Value Measurements [Abstract]
Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis were as follows (in millions): February 29, 2016 Level 1 Level 2 Level 3 Assets Restricted cash (1) $ 175 $ 175 $ - $ - Money market funds (2) 2,659 2,659 - - Available-for-sale investments (3) 1,027 1,027 - - Interest rate swaps (4) 5 - 5 - Foreign currency forwards (5) 1 - 1 - Warrants (6) 1,546 - 1,546 - Liabilities Basis swaps (5) 1 - 1 - Foreign currency forwards (5) 16 - 16 - August 31, 2015 Level 1 Level 2 Level 3 Assets Restricted cash (1) $ 184 $ 184 $ - $ - Money market funds (2) 2,043 2,043 - - Available-for-sale investments (3) 1,183 1,183 - - Interest rate swaps (4) 2 - 2 - Foreign currency forwards (5) 34 - 34 - Warrants (6) 2,140 - 2,140 - Liabilities Foreign currency forwards (5) 9 - 9 - (1) Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations. (2) Money market funds are valued at the closing price reported by the fund sponsor. (3) Fair values of quoted investments are based on current bid prices as of the balance sheet dates. See Note 6, Available-for-Sale Investments for additional information. (4) The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information. (5) The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. (6) Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen’s common stock; AmerisourceBergen’s common stock price at the valuation date; AmerisourceBergen’s equity volatility; the number of shares of AmerisourceBergen’s common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the Warrants.

Retirement Benefits (Tables)

Retirement Benefits (Tables)	6 Months Ended
	Feb. 29, 2016
Boots Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Components of Net Periodic Benefit Cost	Components of net periodic pension costs for the defined benefit pension plans (in millions): Three Months Ended Six Months Ended February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Service costs $ - $ 1 $ 2 $ 1 Interest costs 77 53 159 53 Expected returns on plan assets (62 ) (43 ) (127 ) (43 ) Settlements - 1 - 1 Total net periodic pension costs $ 15 $ 12 $ 34 $ 12
Defined Benefit Postretirement Health Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Components of Net Periodic Benefit Cost	Components of net periodic benefit cost for the postretirement health benefit plan (in millions): Three Months Ended Six Months Ended February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Service cost $ 2 $ 2 $ 5 $ 5 Interest cost 5 4 10 8 Amortization of actuarial loss 5 5 9 10 Amortization of prior service cost (7 ) (6 ) (14 ) (12 ) Total postretirement benefit cost $ 5 $ 5 $ 10 $ 11

Depreciation and Amortization (

Depreciation and Amortization (Tables)	6 Months Ended
	Feb. 29, 2016
Depreciation and Amortization [Abstract]
Depreciation and Amortization by Major Category	The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions): Three Months Ended Six Months Ended February 29, 2016 February 28, 2015 February 29, 2016 February 28, 2015 Depreciation expense $ 346 $ 311 $ 644 $ 567 Intangible asset and other amortization 96 196 180 259 Total depreciation and amortization expense $ 442 $ 507 $ 824 $ 826

Accumulated Other Comprehensi41

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Feb. 29, 2016
Accumulated Other Comprehensive Income (Loss) [Abstract]
Components of Accumulated Other Comprehensive Income (Loss)	The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and six months ended February 29, 2016 and February 28, 2015 (in millions): Pension/Post- retirement Obligations Unrecognized Gain (Loss) on Available-for-Sale Investments Unrealized Gain (Loss) on Cash Flow Hedges Currency Translation Adjustments Total Balance at November 30, 2015 $ 32 $ 260 $ (39 ) $ (911 ) $ (658 ) Other comprehensive income (loss) before reclassification adjustments (4 ) (139 ) - (1,121 ) (1,264 ) Amounts reclassified from accumulated OCI - - 2 - 2 Tax benefit (provision) 2 51 (1 ) - 52 Net other comprehensive income (loss) (2 ) (88 ) 1 (1,121 ) (1,210 ) Balance at February 29, 2016 $ 30 $ 172 $ (38 ) $ (2,032 ) $ (1,868 ) Pension/Post- retirement Obligations Unrecognized Gain (Loss) on Available-for-Sale Investments Unrealized Gain (Loss) on Cash Flow Hedges Currency Translation Adjustments Total Balance at August 31, 2015 $ 29 $ 259 $ (40 ) $ (462 ) $ (214 ) Other comprehensive income (loss) before reclassification adjustments (1 ) (144 ) - (1,570 ) (1,715 ) Amounts reclassified from accumulated OCI - - 3 - 3 Tax benefit (provision) 2 57 (1 ) - 58 Net other comprehensive income (loss) 1 (87 ) 2 (1,570 ) (1,654 ) Balance at February 29, 2016 $ 30 $ 172 $ (38 ) $ (2,032 ) $ (1,868 ) Pension/Post- retirement Obligations Unrecognized Gain (Loss) on Available-for-Sale Investments Unrealized Gain (Loss) on Cash Flow Hedges Share of Alliance Boots OCI Cumulative Translation Adjustments Total Balance at November 30, 2014 $ 14 $ 206 $ (39 ) $ (92 ) $ (35 ) $ 54 Other comprehensive income (loss) before reclassification adjustments (8 ) 140 2 (89 ) (358 ) (313 ) Amounts reclassified from accumulated OCI - - (1 ) 230 80 309 Tax benefit (provision) - (50 ) (1 ) (49 ) (18 ) (118 ) Net other comprehensive income (loss) $ (8 ) $ 90 $ - $ 92 $ (296 ) $ (122 ) Balance at February 28, 2015 $ 6 $ 296 $ (39 ) $ - $ (331 ) $ (68 ) Pension/Post- retirement Obligations Unrecognized Gain (Loss) on Available-for-Sale Investments Unrealized Gain (Loss) on Cash Flow Hedges Share of Alliance Boots OCI Cumulative Translation Adjustments Total Balance at August 31, 2014 $ 15 $ 107 $ (27 ) $ (113 ) $ 154 $ 136 Other comprehensive income (loss) before reclassification adjustments (10 ) 297 (18 ) (57 ) (648 ) (436 ) Amounts reclassified from accumulated OCI - - (1 ) 230 80 309 Tax benefit (provision) 1 (108 ) 7 (60 ) 83 (77 ) Net other comprehensive income (loss) $ (9 ) $ 189 $ (12 ) $ 113 $ (485 ) $ (204 ) Balance at February 28, 2015 $ 6 $ 296 $ (39 ) $ - $ (331 ) $ (68 )

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Feb. 29, 2016
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table reflects results of operations of the Company’s reportable segments (in millions): Retail Pharmacy USA International Pharmaceutical Wholesale Eliminations and Unallocated Items Consolidated Three Months Ended February 29, 2016 Sales to external customers $ 21,500 $ 3,627 $ 5,057 $ - $ 30,184 Intersegment sales - 62 570 (632 ) - Total Sales 21,500 3,689 5,627 (632 ) 30,184 Adjusted Operating Income $ 1,632 $ 335 $ 155 $ (2 ) $ 2,120 Three Months Ended February 28, 2015 Sales to external customers $ 21,048 $ 2,017 $ 3,508 $ - $ 26,573 Intersegment sales - 30 357 (387 ) - Total Sales 21,048 2,047 3,865 (387 ) 26,573 Adjusted Operating Income $ 1,598 $ 125 $ 121 $ (4 ) $ 1,840 Retail Pharmacy USA International Pharmaceutical Wholesale Eliminations and Unallocated Items Consolidated Six Months Ended February 29, 2016 Sales to external customers $ 41,870 $ 7,086 $ 10,261 $ - $ 59,217 Intersegment sales - 134 1,162 (1,296 ) - Total Sales 41,870 7,220 11,423 (1,296 ) 59,217 Adjusted Operating Income $ 2,875 $ 650 $ 321 $ (7 ) $ 3,839 Six Months Ended February 28, 2015 Sales to external customers $ 40,602 $ 2,017 $ 3,508 $ - $ 46,127 Intersegment sales - 30 357 (387 ) - Total Sales 40,602 2,047 3,865 (387 ) 46,127 Adjusted Operating Income $ 2,716 $ 125 $ 121 $ (4 ) $ 2,958
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table reconciles adjusted operating income to operating income (in millions): Retail Pharmacy USA International Pharmaceutical Wholesale Eliminations and Unallocated Items Consolidated Three Months Ended February 29, 2016 Adjusted Operating Income $ 1, 632 $ 335 $ 155 $ (2 ) $ 2,120 Acquisition-related amortization (101 ) Cost transformation (28 ) LIFO provision (68 ) Acquisition-related costs (33 ) Asset impairment (30 ) Operating Income $ 1,860 Three Months Ended February 28, 2015 Adjusted Operating Income $ 1,598 $ 125 $ 121 $ (4 ) $ 1,840 (Decrease) increase in fair market value of warrants (6 ) Acquisition-related amortization (217 ) LIFO provision (55 ) Acquisition-related costs (59 ) Asset impairment (110 ) Store closures and other optimization costs (16 ) Operating Income $ 1,377 Retail Pharmacy USA International Pharmaceutical Wholesale Eliminations and Unallocated Items Consolidated Six Months Ended February 29, 2016 Adjusted Operating Income $ 2,875 $ 650 $ 321 $ (7 ) $ 3,839 Acquisition-related amortization (182 ) Cost transformation (118 ) LIFO provision (114 ) Acquisition-related costs (67 ) Asset impairment (30 ) Operating Income $ 3,328 Six Months Ended February 28, 2015 Adjusted Operating Income $ 2,716 $ 125 $ 121 $ (4 ) $ 2,958 (Decrease) increase in fair market value of warrants 123 Acquisition-related amortization (306 ) LIFO provision (107 ) Acquisition-related costs (83 ) Asset impairment (110 ) Store closures and other optimization costs (44 ) Operating Income $ 2,431

Organization (Details)

Organization (Details) £ in Millions	Dec. 31, 2014USD ($)shares	Dec. 31, 2014GBP (£)shares	Feb. 29, 2016USD ($)Segmentshares	Aug. 31, 2015shares	Jan. 01, 2015shares
Schedule of Equity Method Investments [Line Items]
Number of reportable segment | Segment			3
Total purchase price cash consideration	$ 4,900,000,000	£ 3,133
Common shares transfer (in shares)			1,172,513,618	1,172,513,618
Walgreens Boots Alliance [Member]
Schedule of Equity Method Investments [Line Items]
Noncontrolling interest	55.00%	55.00%
Total purchase price cash consideration | £		£ 3,133
Number of shares exchanged in acquisition (in shares)	144,300,000	144,300,000
Walgreens Boots Alliance Development GmbH [Member]
Schedule of Equity Method Investments [Line Items]
Noncontrolling interest			27.50%
Ownership interest percentage prior to Second Step Transaction			50.00%
Ownership percentage			72.50%
Alliance Boots [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage	45.00%	45.00%	45.00%
Alliance Healthcare Italia Distribuzione S.p.A. [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage					5.00%
Common shares transfer (in shares)					320
Equity method ownership option to repurchase shares, amount | $			$ 100,000

Restructuring (Details)

Restructuring (Details) $ in Millions	3 Months Ended		6 Months Ended		18 Months Ended
	Feb. 29, 2016USD ($)Stores	Feb. 28, 2015USD ($)	Feb. 29, 2016USD ($)Stores	Feb. 28, 2015USD ($)	Feb. 29, 2016USD ($)Stores
Restructuring Reserve Disclosures [Abstract]
Pre-tax charges incurred during the period					$ 660
Total restructuring costs	$ 28	$ 0	$ 118	$ 17
Retail Pharmacy USA [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	25	0	110	17
Retail Pharmacy International [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	3	0	8	0
Pharmaceutical Wholesale [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	0	0	0	0
Real Estate Costs [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	0	0	52	17
Real Estate Costs [Member] | Retail Pharmacy USA [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	0	0	52	17
Real Estate Costs [Member] | Retail Pharmacy International [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	0	0	0	0
Real Estate Costs [Member] | Pharmaceutical Wholesale [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	0	0	0	0
Asset Impairments [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	0	0	25	0
Asset Impairments [Member] | Retail Pharmacy USA [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	0	0	25	0
Asset Impairments [Member] | Retail Pharmacy International [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	0	0	0	0
Asset Impairments [Member] | Pharmaceutical Wholesale [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	0	0	0	0
Severance and Other Business Transition and Exit Costs [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	28	0	41	0
Severance and Other Business Transition and Exit Costs [Member] | Retail Pharmacy USA [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	25	0	33	0
Severance and Other Business Transition and Exit Costs [Member] | Retail Pharmacy International [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	3	0	8	0
Severance and Other Business Transition and Exit Costs [Member] | Pharmaceutical Wholesale [Member]
Restructuring Reserve Disclosures [Abstract]
Total restructuring costs	$ 0	0	$ 0	0
Lease Termination Costs [Member]
Restructuring Reserve Disclosures [Abstract]
Pre-tax charges incurred during the period		17
Cost Transformation Program [Member]
Restructuring Reserve Disclosures [Abstract]
Number of stores planned to be closed | Stores	200		200		200
Pre-tax charges incurred during the period	$ 28	$ 0	$ 118	$ 0
Cost Transformation Program [Member] | Minimum [Member]
Restructuring Reserve Disclosures [Abstract]
Expected pre-tax charges	1,600		1,600		$ 1,600
Cost Transformation Program [Member] | Maximum [Member]
Restructuring Reserve Disclosures [Abstract]
Expected pre-tax charges	1,800		1,800		1,800
Cost Transformation Program [Member] | Real Estate Costs [Member]
Restructuring Reserve Disclosures [Abstract]
Pre-tax charges incurred during the period					254
Cost Transformation Program [Member] | Real Estate Costs [Member] | Minimum [Member]
Restructuring Reserve Disclosures [Abstract]
Expected pre-tax charges	525		525		525
Cost Transformation Program [Member] | Real Estate Costs [Member] | Maximum [Member]
Restructuring Reserve Disclosures [Abstract]
Expected pre-tax charges	600		600		600
Cost Transformation Program [Member] | Asset Impairments [Member]
Restructuring Reserve Disclosures [Abstract]
Pre-tax charges incurred during the period					248
Cost Transformation Program [Member] | Asset Impairments [Member] | Minimum [Member]
Restructuring Reserve Disclosures [Abstract]
Expected pre-tax charges	650		650		650
Cost Transformation Program [Member] | Asset Impairments [Member] | Maximum [Member]
Restructuring Reserve Disclosures [Abstract]
Expected pre-tax charges	725		725		725
Cost Transformation Program [Member] | Severance and Other Business Transition and Exit Costs [Member]
Restructuring Reserve Disclosures [Abstract]
Pre-tax charges incurred during the period					158
Cost Transformation Program [Member] | Severance and Other Business Transition and Exit Costs [Member] | Minimum [Member]
Restructuring Reserve Disclosures [Abstract]
Expected pre-tax charges	425		425		425
Cost Transformation Program [Member] | Severance and Other Business Transition and Exit Costs [Member] | Maximum [Member]
Restructuring Reserve Disclosures [Abstract]
Expected pre-tax charges	$ 475		$ 475		$ 475

Operating Leases (Details)

Operating Leases (Details) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 29, 2016USD ($)Lease	Feb. 28, 2015USD ($)	Feb. 29, 2016USD ($)Lease	Feb. 28, 2015USD ($)	Aug. 31, 2015USD ($)
Operating Leases [Abstract]
Initial term of operating lease, lower range			15 years
Initial term of operating lease, upper range			25 years
Interval period of renewal options			5 years
Charges related to facilities that were closed or relocated	$ 9	$ 0	$ 75	$ 26
Changes in reserve for facility closings and related lease termination charges [Roll Forward]
Balance - beginning of period			446	$ 257	$ 257
Provision for present value of non-cancellable lease payments on closed facilities			77		231
Assumptions about future sublease income, terminations and changes in interest rates			(14)		(6)
Interest accretion			12		27
Liability assumed through acquisition of Alliance Boots			0		13
Cash payments, net of sublease income			(54)		(76)
Balance - end of period	$ 467		$ 467		$ 446
Number of leases | Lease	79		79
Maximum potential undiscounted future payments	$ 348		$ 348

Equity Method Investments, Equi

Equity Method Investments, Equity Method Investments (Details) - USD ($) $ in Millions	Feb. 29, 2016	Aug. 31, 2015
Schedule of Equity Method Investments [Line Items]
Carrying Value	$ 1,217	$ 1,242
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership interest percentage	12.00%	12.00%
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership interest percentage	50.00%	50.00%

Equity Method Investments (Deta

Equity Method Investments (Details) - USD ($) $ in Millions		3 Months Ended			6 Months Ended
		Feb. 29, 2016	Feb. 28, 2015		Feb. 29, 2016	Feb. 28, 2015		Aug. 31, 2015	Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]
Non-controlling interests		$ 170			$ 170			$ 163
Equity earnings	[1]	$ 9	$ 109	[2]	$ 20	$ 323	[2]
Alliance Boots [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings			101			315
Equity method investment ownership interest percentage		45.00%			45.00%				45.00%
Other Equity Method Investments [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings		$ 9	$ 8		$ 20	$ 8
[1]	Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates.
[2]	Includes equity method investment in Alliance Boots from Walgreen Co.'s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.

Equity Method Investments, Summ

Equity Method Investments, Summarized Financial Information of Equity Method Investees (Details) - USD ($) $ in Millions		3 Months Ended			6 Months Ended
		Feb. 29, 2016	Feb. 28, 2015	[4]	Feb. 29, 2016	Feb. 28, 2015	[4]	Aug. 31, 2015
Balance Sheet [Abstract]
Current assets	[1]	$ 5,687			$ 5,687			$ 5,015
Noncurrent assets	[1]	1,592			1,592			1,548
Current liabilities	[1]	4,598			4,598			3,936
Noncurrent liabilities	[1]	876			876			837
Shareholders' equity	[1],[2]	1,805			1,805			$ 1,790
Statements of Earnings [Abstract]
Net sales	[3]	3,286	$ 5,317		6,489	$ 14,978
Gross Profit	[3]	374	979		702	3,168
Net Income	[3]	26	246		50	743
Share of income from equity method investments	[3]	$ 9	$ 109		$ 20	$ 323
[1]	Balance sheet information of foreign equity method investments are translated at their respective February 29, 2016 and August 31, 2015 spot rates.
[2]	Shareholders' equity at February 29, 2016 and August 31, 2015 includes $170 million and $163 million, respectively, related to noncontrolling interests.
[3]	Statement of earnings information of foreign equity method investments are translated at their respective average exchange rates.
[4]	Includes equity method investment in Alliance Boots from Walgreen Co.'s pre-merger 45 percent interest for one month (December 2014) and four months (September through December 2014), respectively. See Note 1, Organization.

Available-for-Sale Investment49

Available-for-Sale Investments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015	Aug. 31, 2015
Summary of cost and fair value of available-for-sale securities [Abstract]
Amortized cost basis	$ 755		$ 755		$ 754
Gross unrealized gains	276		276		430
Gross unrealized losses	(4)		(4)		(1)
Fair value	$ 1,027		$ 1,027		1,183
AmerisourceBergen Common Stock [Member]
Schedule of Available-for-sale Securities [Line Items]
Maximum number of shares in minority equity position (in shares)	19,859,795		19,859,795
Percentage of outstanding common stock held	5.60%		5.60%
Sale of acquired available-for-sale securities	$ 1	$ 0	$ 3	$ 0
Number of shares held (in shares)	11,500,000		11,500,000
Summary of cost and fair value of available-for-sale securities [Abstract]
Amortized cost basis	$ 717		$ 717		717
Gross unrealized gains	276		276		430
Gross unrealized losses	0		0		0
Fair value	993		993		1,147
Other Investments [Member]
Summary of cost and fair value of available-for-sale securities [Abstract]
Amortized cost basis	38		38		37
Gross unrealized gains	0		0		0
Gross unrealized losses	(4)		(4)		(1)
Fair value	$ 34		$ 34		$ 36

Acquisitions (Details)

Acquisitions (Details) $ / shares in Units, £ in Millions	Dec. 31, 2014USD ($)shares	Dec. 31, 2014GBP (£)shares	Feb. 29, 2016USD ($)shares	Aug. 31, 2015USD ($)shares	Jan. 15, 2015	Dec. 31, 2014$ / €	Dec. 30, 2014$ / shares
Business Acquisition [Line Items]
Common shares transfer (in shares) | shares			1,172,513,618	1,172,513,618
Total purchase price	$ 15,900,000,000		$ 13,300,000,000
Noncontrolling interest acquired			$ 412,000,000	$ 439,000,000
Total purchase price cash consideration	$ 4,900,000,000	£ 3,133
Spot rate	1.56	1.56				1
Purchase price consideration, common shares (in shares) | shares	144,300,000	144,300,000
Purchase price consideration common shares fair value	$ 11,000,000,000
Closing market price per share (in dollars per share) | $ / shares							$ 76.05
Alliance Boots [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of issued and outstanding capital acquired	55.00%	55.00%
Equity method investment ownership interest percentage			45.00%
Noncontrolling interest	100.00%	100.00%
Total purchase price			$ 15,851,000,000
Total purchase price cash consideration			4,874,000,000
Purchase price consideration common shares fair value			8,149,000,000
Impact of equity transactions [Abstract]
Consideration attributable to WBAD			2,559,000,000
Less: Carrying value of the Company's pre-existing noncontrolling interest			130,000,000
Impact to additional paid in capital			$ 2,429,000,000
Alliance Boots [Member] | Previously Reported [Member]
Business Acquisition [Line Items]
Equity method investment ownership interest percentage			45.00%
Walgreens Boots Alliance Development GmbH [Member]
Business Acquisition [Line Items]
Ownership interest percentage prior to Second Step Transaction			50.00%
Noncontrolling interest	100.00%	100.00%	27.50%
Noncontrolling interest acquired			$ 2,600,000,000
Alliance Healthcare Italia Distribuzione S.p.A. [Member]
Business Acquisition [Line Items]
Equity method investment ownership interest percentage					5.00%
Common shares transfer (in shares) | shares			320
Equity method ownership option to repurchase shares, amount			$ 100,000

Acquisitions, Consideration Pai

Acquisitions, Consideration Paid (Details) £ in Millions, $ in Millions	Dec. 31, 2014USD ($)	Dec. 31, 2014GBP (£)	Feb. 29, 2016USD ($)
Consideration paid [Abstract]
Cash	$ 4,900	£ 3,133
Total consideration transferred	15,900		$ 13,300
Fair value of the investment in Alliance Boots held before the Second Step Transaction	$ 11,000
Alliance Boots [Member]
Consideration paid [Abstract]
Cash			4,874
Common stock			10,977
Total consideration transferred			15,851
Less: consideration attributed to WBAD			(2,559)
Total consideration after attributed amount to WBAD			13,292
Fair value of the investment in Alliance Boots held before the Second Step Transaction			8,149
Total consideration			$ 21,441

Acquisitions, Identifiable Asse

Acquisitions, Identifiable Assets Acquired and Liabilities Assumed Including Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015	Aug. 31, 2015
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Goodwill	$ 15,796		$ 15,796		$ 16,372
Gain on previously held equity interest	0	$ 706	0	$ 706
Alliance Boots [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Cash and cash equivalents	413		413
Accounts receivable	3,799		3,799
Inventories	3,713		3,713
Other current assets	894		894
Property, plant and equipment	3,806		3,806
Intangible assets	11,691		11,691
Other non-current assets	2,217		2,217
Trade accounts payable, accrued expenses and other liabilities	(7,696)		(7,696)
Borrowings	(9,010)		(9,010)
Deferred income taxes	(2,452)		(2,452)
Other non-current liabilities	(383)		(383)
Noncontrolling interests	(412)		(412)
Total identifiable net assets and noncontrolling interests	6,580		6,580
Goodwill	$ 14,861		14,861
Gain on previously held equity interest			563
Fair value of previously held equity interest			$ 8,100

Acquisitions, The Identified De

Acquisitions, The Identified Definite and Indefinite Lived Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015	Aug. 31, 2015
Indefinite-Lived Intangible Assets [Roll Forward]
Goodwill	$ 15,796		$ 15,796		$ 16,372
Selling, general and administrative expenses	6,084	$ 5,606	12,118	$ 10,062
Fair value of the assets acquired			3,700
Estimated manufacturing profit in acquired finished goods inventory capitalized	106		106
Retail Pharmacy International [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Goodwill	3,605		3,605		3,898
Retail Pharmacy USA [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Goodwill	8,940		8,940		8,940
Goodwill arising from synergies			3,500
Goodwill based on a with and without analysis			3,800
Pharmaceutical Wholesale [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Goodwill	3,251		3,251		3,534
Alliance Boots [Member]
Definite-Lived Intangible Assets [Roll Forward]
Amount			2,545
Indefinite-Lived Intangible Assets [Roll Forward]
Amount			9,146
Goodwill	$ 14,861		$ 14,861
Equity interest in Alliance Boots	45.00%		45.00%
Selling, general and administrative expenses	$ 0	$ 59	$ 0	$ 83	$ 87
Trade Names and Trademarks [Member] | Alliance Boots [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Amount			6,657
Pharmacy Licenses [Member] | Alliance Boots [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Amount			$ 2,489
Customer Relationships [Member] | Alliance Boots [Member]
Definite-Lived Intangible Assets [Roll Forward]
Weighted-Average Useful Life			12 years
Amount			$ 1,311
Loyalty Card Holders [Member] | Alliance Boots [Member]
Definite-Lived Intangible Assets [Roll Forward]
Weighted-Average Useful Life			20 years
Amount			$ 742
Trade Names and Trademarks [Member] | Alliance Boots [Member]
Definite-Lived Intangible Assets [Roll Forward]
Weighted-Average Useful Life			9 years
Amount			$ 399
Favorable Lease Interests [Member] | Alliance Boots [Member]
Definite-Lived Intangible Assets [Roll Forward]
Weighted-Average Useful Life			7 years
Amount			$ 93

Acquisitions, Unaudited Pro For

Acquisitions, Unaudited Pro Forma Results Prepared for Comparative Purposes (Details) - Alliance Boots [Member] - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	6 Months Ended
	Feb. 28, 2015	Feb. 28, 2015
Business Acquisition [Line Items]
Net sales	$ 30,202	$ 59,173
Net earnings	$ 1,253	$ 2,621
Net earnings per common share [Abstract]
Basic (in dollars per share)	$ 1.20	$ 2.51
Diluted (in dollars per share)	$ 1.19	$ 2.49

Acquisitions, Actual Results fr

Acquisitions, Actual Results from Alliance Boots Operations Included in the Consolidated Condensed Statements of Earnings (Details) - USD ($) $ in Millions	6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
Business Acquisition [Line Items]
Aggregate purchase price	$ 0	$ 4,461
Goodwill	19
Other Acquisition [Member]
Business Acquisition [Line Items]
Aggregate purchase price	86
Goodwill	19
Intangible assets	$ 72

Goodwill and Other Intangible56

Goodwill and Other Intangible Assets, Schedule of Goodwill (Details) $ in Millions	6 Months Ended
	Feb. 29, 2016USD ($)
Goodwill [Roll Forward]
Net book value - Beginning Period	$ 16,372
Acquisitions	19
Other	10	[1]
Currency translation adjustments	(605)
Net book value - Ending Period	15,796
Retail Pharmacy USA [Member]
Goodwill [Roll Forward]
Net book value - Beginning Period	8,940
Acquisitions	0
Other	0	[1]
Currency translation adjustments	0
Net book value - Ending Period	8,940
Retail Pharmacy International [Member]
Goodwill [Roll Forward]
Net book value - Beginning Period	3,898
Acquisitions	19
Other	(3)	[1]
Currency translation adjustments	(309)
Net book value - Ending Period	3,605
Pharmaceutical Wholesale [Member]
Goodwill [Roll Forward]
Net book value - Beginning Period	3,534
Acquisitions	0
Other	13	[1]
Currency translation adjustments	(296)
Net book value - Ending Period	$ 3,251
[1]	Other represents immaterial purchase accounting adjustments for prior year Company acquisitions.

Goodwill and Other Intangible57

Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets by Major Class (Details) - USD ($) $ in Millions	Feb. 29, 2016	Aug. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	$ 4,246	$ 4,387
Accumulated amortization	1,293	1,090
Total amortizable intangible assets, net	2,953	3,297
Total indefinite lived intangible assets	8,169	9,054
Total intangible assets, net	11,122	12,351
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	1,293	1,409
Accumulated amortization	182	132
Purchased Prescription Files [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	904	885
Accumulated amortization	536	470
Loyalty Card Holders [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	661	730
Accumulated amortization	41	41
Favorable Lease Interests [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	457	440
Accumulated amortization	246	207
Non-compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	158	154
Accumulated amortization	106	92
Purchasing and Payer Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	95	94
Accumulated amortization	68	65
Trade Names and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	678	675
Accumulated amortization	114	83
Total indefinite lived intangible assets	5,947	6,590
Pharmacy Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	$ 2,222	$ 2,464

Goodwill and Other Intangible58

Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Goodwill and Other Intangible Assets [Abstract]
Amortization expense for intangible assets	$ 124	$ 209	$ 216	$ 276

Goodwill and Other Intangible59

Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Millions	Feb. 29, 2016USD ($)
Estimated annual intangible assets amortization expense [Abstract]
2,016	$ 401
2,017	358
2,018	318
2,019	289
2,020	$ 254

Short-Term Borrowings and Lon60

Short-Term Borrowings and Long-Term Debt, Short-Term Borrowings (Details) - USD ($) $ in Millions		6 Months Ended
		Feb. 29, 2016	Aug. 31, 2015
Short-Term Borrowings [Abstract]
Other		$ 1,052	$ 1,068
Unsecured Variable Rate Notes Due 2016 [Member]
Short-Term Borrowings [Abstract]
Unsecured Notes	[1]	$ 749	747
Maturity year	[1]	2,016
Other Short-Term Debt [Member]
Short-Term Borrowings [Abstract]
Other	[1],[2]	$ 303	321
Total short-term borrowings	[1]	$ 1,052	$ 1,068
[1]	All notes are presented net of unamortized discount and debt issuance costs, where applicable.
[2]	Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.

Short-Term Borrowings and Lon61

Short-Term Borrowings and Long-Term Debt, Long-Term Debt (Details) $ in Millions		6 Months Ended
		Feb. 29, 2016USD ($)$ / €$ / £	Aug. 31, 2015USD ($)$ / €$ / £
Long-Term Debt [Abstract]
Other	[1],[2]	$ 42	$ 44
Total long term debt	[1]	12,974	13,315
Unsecured Pound Sterling Variable Rate Term Loan Due 2019 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1],[3]	$ 2,013	2,229
Maturity year	[1],[3]	2,019
1.750% Unsecured Notes Due 2017 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1]	$ 747	746
Interest rate	[1]	1.75%
Maturity year	[1]	2,017
5.250% Unsecured Notes Due 2019 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1],[4]	$ 253	250
Interest rate	[1],[4]	5.25%
Maturity year	[1],[4]	2,019
2.700% Unsecured Notes Due 2019 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1]	$ 1,244	1,243
Interest rate	[1]	2.70%
Maturity year	[1]	2,019
2.875% Unsecured Pound Sterling Notes Due 2020 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1],[3]	$ 552	$ 612
Interest rate	[1],[3]	2.875%
Maturity year	[1],[3]	2,020
Spot rate | $ / £		1.39	1.54
3.300% Unsecured Notes Due 2021 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1]	$ 1,241	$ 1,241
Interest rate	[1]	3.30%
Maturity year	[1]	2,021
3.100% Unsecured Notes Due 2022 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1]	$ 1,193	1,193
Interest rate	[1]	3.10%
Maturity year	[1]	2,022
3.800% Unsecured Notes Due 2024 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1]	$ 1,986	1,985
Interest rate	[1]	3.80%
Maturity year	[1]	2,024
3.600% Unsecured Pound Sterling Notes Due 2025 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1],[3]	$ 414	$ 459
Interest rate	[1],[3]	3.60%
Maturity year	[1],[3]	2,025
Spot rate | $ / £		1.39	1.54
2.125% Unsecured Euro Notes Due 2026 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1],[5]	$ 811	$ 836
Interest rate	[1],[5]	2.125%
Maturity year	[1],[5]	2,026
Spot rate | $ / €		1.09	1.12
4.500% Unsecured Notes Due 2034 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1]	$ 494	$ 494
Interest rate	[1]	4.50%
Maturity year	[1]	2,034
4.400% Unsecured Notes Due 2042 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1]	$ 492	492
Interest rate	[1]	4.40%
Maturity year	[1]	2,042
4.800% Unsecured Notes Due 2044 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	[1]	$ 1,492	$ 1,491
Interest rate	[1]	4.80%
Maturity year	[1]	2,044
Unsecured Debt [Member] | 1.750% Unsecured Notes Due 2017 [Member]
Long-Term Debt [Abstract]
Interest rate		1.75%
Unsecured Debt [Member] | 3.300% Unsecured Notes Due 2021 [Member]
Long-Term Debt [Abstract]
Interest rate		3.30%
Unsecured Debt [Member] | 3.100% Unsecured Notes Due 2022 [Member]
Long-Term Debt [Abstract]
Interest rate		3.10%
Unsecured Debt [Member] | 3.800% Unsecured Notes Due 2024 [Member]
Long-Term Debt [Abstract]
Interest rate		3.80%
Unsecured Debt [Member] | 4.500% Unsecured Notes Due 2034 [Member]
Long-Term Debt [Abstract]
Interest rate		4.50%
Unsecured Debt [Member] | 4.400% Unsecured Notes Due 2042 [Member]
Long-Term Debt [Abstract]
Interest rate		4.40%
Unsecured Debt [Member] | 4.800% Unsecured Notes Due 2044 [Member]
Long-Term Debt [Abstract]
Interest rate		4.80%
[1]	All notes are presented net of unamortized discount and debt issuance costs, where applicable.
[2]	Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
[3]	Pound Sterling denominated notes are translated at the spot rates of $1.39 and $1.54 to one British Pound Sterling at February 29, 2016 and August 31, 2015, respectively.
[4]	Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.
[5]	Euro denominated notes are translated at the spot rates of $1.09 and $1.12 to one Euro at February 29, 2016 and August 31, 2015, respectively.

Short-Term Borrowings and Lon62

Short-Term Borrowings and Long-Term Debt (Details) £ in Millions, $ in Millions	6 Months Ended
	Feb. 29, 2016USD ($)	Feb. 29, 2016GBP (£)	Aug. 10, 2015
Long-Term Debt [Abstract]
Percentage of principal amount of fixed rate notes can be redeemed	100.00%
Total $8.0 Billion Debt Issuance [Member]
Long-Term Debt [Abstract]
Net proceeds from notes payable	$ 7,900
Total issuance costs	44
Fair value of the notes	$ 7,900
Percentage of principal amount of fixed rate notes can be redeemed	100.00%
Percentage of principal amount required on triggering event to repurchase notes	101.00%	101.00%
Total $4.0 Billion Debt Issuance [Member]
Long-Term Debt [Abstract]
Repayment of debt	$ 1,000
Net proceeds from notes payable	4,000
Total issuance costs	26
Fair value of the notes	$ 1,600
Percentage of principal amount of fixed rate notes can be redeemed	100.00%
Percentage of redemption price	100.00%
Percentage of principal amount required on triggering event to repurchase notes	101.00%	101.00%
Percentage of redemption price including accrued interest	101.677%
Debt instrument redemption premium	$ 17
Total $1.0 Billion Debt Issuance [Member]
Long-Term Debt [Abstract]
Repayment of debt	750
Net proceeds from notes payable	1,000
Total issuance costs	8
Fair value of the notes	$ 270
Stated interest rate	5.25%	5.25%
Percentage of principal amount of fixed rate notes can be redeemed	100.00%
Percentage of principal amount required on triggering event to repurchase notes	101.00%	101.00%
Percentage of redemption price including accrued interest	111.734%
Debt instrument redemption premium	$ 88
Face amount of notes issued	$ 250
Total $1.0 Billion Debt Issuance [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.45%
Euro and Pound Sterling Notes [Member]
Long-Term Debt [Abstract]
Total issuance costs	$ 11
Fair value of the notes	$ 1,800
Percentage of redemption price	100.00%
Percentage of principal amount required on triggering event to repurchase notes	101.00%	101.00%
Euro Notes [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.20%
1.750% Unsecured Notes Due 2017 [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.15%
2.700% Unsecured Notes Due 2019 [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.15%
3.300% Unsecured Notes Due 2021 [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.20%
3.800% Unsecured Notes Due 2024 [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.20%
4.500% Unsecured Notes Due 2034 [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.20%
4.800% Unsecured Notes Due 2044 [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.25%
Notes Due 2014 [Member]
Long-Term Debt [Abstract]
Repayment of debt	$ 550
1.000% Unsecured Notes Due 2015 [Member]
Long-Term Debt [Abstract]
Repayment of debt	$ 750
1.000% Unsecured Notes Due 2015 [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.12%
1.800% Unsecured Notes Due 2017 [Member]
Long-Term Debt [Abstract]
Stated interest rate			1.80%
3.100% Unsecured Notes Due 2022 [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.22%
4.400% Unsecured Notes Due 2042 [Member] | Treasury Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.25%
Unsecured Pound Sterling Notes Due 2020 [Member] | Government Bond Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.20%
Unsecured Pound Sterling Notes Due 2025 [Member] | Government Bond Rate [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate	0.20%
Unsecured Debt [Member] | Total $8.0 Billion Debt Issuance [Member]
Long-Term Debt [Abstract]
Face amount of notes issued	$ 8,000
Unsecured Debt [Member] | Total $4.0 Billion Debt Issuance [Member]
Long-Term Debt [Abstract]
Face amount of notes issued	$ 1,700
Unsecured Debt [Member] | Unsecured Pound Sterling Notes Due 2020 [Member]
Long-Term Debt [Abstract]
Stated interest rate	2.875%	2.875%
Face amount of notes issued | £		£ 400
Unsecured Debt [Member] | Unsecured Pound Sterling Notes Due 2025 [Member]
Long-Term Debt [Abstract]
Stated interest rate	3.60%	3.60%
Face amount of notes issued | £		£ 300

Short-Term Borrowings and Lon63

Short-Term Borrowings and Long-Term Debt, Debt Issuance (Details) € in Millions, £ in Millions, $ in Millions	6 Months Ended
	Feb. 29, 2016USD ($)		Feb. 29, 2016GBP (£)		Feb. 29, 2016EUR (€)
1.750% Unsecured Notes Due 2017 [Member]
Debt Instrument [Line Items]
Interest rate	1.75%	[1]	1.75%	[1]	1.75%	[1]
2.875% Unsecured Pound Sterling Notes Due 2020 [Member]
Debt Instrument [Line Items]
Maturity date	Nov. 20, 2020
3.300% Unsecured Notes Due 2021 [Member]
Debt Instrument [Line Items]
Interest rate	3.30%	[1]	3.30%	[1]	3.30%	[1]
3.100% Unsecured Notes Due 2022 [Member]
Debt Instrument [Line Items]
Interest rate	3.10%	[1]	3.10%	[1]	3.10%	[1]
3.800% Unsecured Notes Due 2024 [Member]
Debt Instrument [Line Items]
Interest rate	3.80%	[1]	3.80%	[1]	3.80%	[1]
2.125% Unsecured Euro Notes Due 2026 [Member]
Debt Instrument [Line Items]
Maturity date	Nov. 20, 2026
4.500% Unsecured Notes Due 2034 [Member]
Debt Instrument [Line Items]
Interest rate	4.50%	[1]	4.50%	[1]	4.50%	[1]
4.400% Unsecured Notes Due 2042 [Member]
Debt Instrument [Line Items]
Interest rate	4.40%	[1]	4.40%	[1]	4.40%	[1]
4.800% Unsecured Notes Due 2044 [Member]
Debt Instrument [Line Items]
Interest rate	4.80%	[1]	4.80%	[1]	4.80%	[1]
Unsecured Debt [Member] | Unsecured Variable Rate Notes Due 2016 [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 750
Maturity date	May 18, 2016
Interest payment dates	February 18, May 18, August 18, and November 18; commencing on February 18, 2015
Debt instrument, description of variable rate basis	Three-month U.S. Dollar LIBOR
Basis spread on variable rate	0.45%
Unsecured Debt [Member] | 1.750% Unsecured Notes Due 2017 [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 750
Maturity date	Nov. 17, 2017
Interest payment dates	May 17 and November 17; commencing on May 17, 2015
Interest rate	1.75%		1.75%		1.75%
Unsecured Debt [Member] | 2.700% Unsecured Notes Due 2019 [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 1,250
Maturity date	Nov. 18, 2019
Interest payment dates	May 18 and November 18; commencing on May 18, 2015
Interest rate	2.70%		2.70%		2.70%
Unsecured Debt [Member] | 2.875% Unsecured Pound Sterling Notes Due 2020 [Member]
Debt Instrument [Line Items]
Face amount of notes issued | £			£ 400
Interest rate	2.875%		2.875%		2.875%
Unsecured Debt [Member] | 3.300% Unsecured Notes Due 2021 [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 1,250
Maturity date	Nov. 18, 2021
Interest payment dates	May 18 and November 18; commencing on May 18, 2015
Interest rate	3.30%		3.30%		3.30%
Unsecured Debt [Member] | 3.100% Unsecured Notes Due 2022 [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 1,200
Maturity date	Sep. 15, 2022
Interest payment dates	March 15 and September 15; commencing on March 15, 2013
Interest rate	3.10%		3.10%		3.10%
Unsecured Debt [Member] | 3.800% Unsecured Notes Due 2024 [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 2,000
Maturity date	Nov. 18, 2024
Interest payment dates	May 18 and November 18; commencing on May 18, 2015
Interest rate	3.80%		3.80%		3.80%
Unsecured Debt [Member] | 3.600% Unsecured Pound Sterling Notes Due 2025 [Member]
Debt Instrument [Line Items]
Face amount of notes issued | £			£ 300
Maturity date	Nov. 20, 2025
Interest rate	3.60%		3.60%		3.60%
Unsecured Debt [Member] | 2.125% Unsecured Euro Notes Due 2026 [Member]
Debt Instrument [Line Items]
Face amount of notes issued | €					€ 750
Interest rate	2.125%		2.125%		2.125%
Unsecured Debt [Member] | 4.500% Unsecured Notes Due 2034 [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 500
Maturity date	Nov. 18, 2034
Interest payment dates	May 18 and November 18; commencing on May 18, 2015
Interest rate	4.50%		4.50%		4.50%
Unsecured Debt [Member] | 4.400% Unsecured Notes Due 2042 [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 500
Maturity date	Sep. 15, 2042
Interest payment dates	March 15 and September 15; commencing on March 15, 2013
Interest rate	4.40%		4.40%		4.40%
Unsecured Debt [Member] | 4.800% Unsecured Notes Due 2044 [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 1,500
Maturity date	Nov. 18, 2044
Interest payment dates	May 18 and November 18; commencing on May 18, 2015
Interest rate	4.80%		4.80%		4.80%
Unsecured Debt [Member] | Pound Sterling Notes [Member]
Debt Instrument [Line Items]
Face amount of notes issued | £			£ 700
Unsecured Debt [Member] | Total $4.0 Billion Debt Issuance [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 1,700
Unsecured Debt [Member] | Total $8.0 Billion Debt Issuance [Member]
Debt Instrument [Line Items]
Face amount of notes issued	$ 8,000
[1]	All notes are presented net of unamortized discount and debt issuance costs, where applicable.

Short-Term Borrowings and Lon64

Short-Term Borrowings and Long-Term Debt, Other Borrowings (Details) £ in Millions, $ in Millions	6 Months Ended
	Feb. 29, 2016USD ($)Tranche	Feb. 28, 2015USD ($)	Feb. 29, 2016GBP (£)	Dec. 18, 2015USD ($)	Oct. 27, 2015USD ($)	Dec. 31, 2014	Dec. 31, 2014$ / €	Dec. 29, 2014USD ($)	Nov. 10, 2014USD ($)
Line of Credit Facility [Line Items]
Spot rate						1.56	1
Senior unsecured bridge facility				$ 7,800	$ 12,800
Additional senior unsecured bridge facility				2,000
United Kingdom, Pounds
Line of Credit Facility [Line Items]
Spot rate	1.39		1.39
Commercial Paper [Member]
Line of Credit Facility [Line Items]
Balance outstanding at fiscal year-end	$ 0	$ 0
Average daily short-term borrowings	$ 20	$ 4
Weighted-average interest rate	0.62%	0.46%	0.62%
Additional Bridge Loan [Member]
Line of Credit Facility [Line Items]
Fees related to borrowings	$ 5
Senior unsecured bridge facility				$ 3,000
Term of credit agreement	90 days
Bridge Credit Agreement [Member]
Line of Credit Facility [Line Items]
Amount borrowed	$ 0
Term of credit agreement	364 days
Term Loan [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 2,000		£ 1,450
Amount borrowed	2,000		£ 1,450
Fair value of the notes	$ 2,000
Term Loan [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Debt to total capitalization ratio	0.60		0.60
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity								$ 3	$ 2,250
Amount borrowed	$ 0
Term of facility	5 years
Revolving Credit Facility [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Debt to total capitalization ratio	0.60		0.60
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity								$ 500	$ 375
Term Loan and Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Fees related to borrowings	$ 14
364-Day Credit Agreement [Member]
Line of Credit Facility [Line Items]
Amount borrowed	$ 750
Termination of credit agreement	Dec. 17, 2015
364-Day Credit Agreement [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Debt to total capitalization ratio	0.60		0.60
Term Loan Credit Agreement [Member]
Line of Credit Facility [Line Items]
Amount borrowed	$ 0
Number of tranches | Tranche	2
Term loan amount	$ 5,000
2015 Credit Agreements [Member]
Line of Credit Facility [Line Items]
Fees related to borrowings	$ 30
2015 Credit Agreements [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Debt to total capitalization ratio	0.60		0.60
Tranche One [Member]
Line of Credit Facility [Line Items]
Term of credit agreement	3 years
Tranche Two [Member]
Line of Credit Facility [Line Items]
Term of credit agreement	5 years

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended		6 Months Ended
		Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015	Aug. 31, 2015	Aug. 10, 2015
Effect of Fair Value Hedges on Results of Operations [Abstract]
Cumulative fair value adjustments resulted in increase in long-term debt		$ 4	$ 1	$ 4	$ 1
Interest Rate Swaps [Member] | One-month LIBOR [Member]
Derivatives, Fair Value [Line Items]
Derivatives assets, Fair Value		$ 250		$ 250
Fixed interest rate percentage		5.25%		5.25%
Interest Rate Swaps [Member] | Six-month LIBOR [Member]
Derivatives, Fair Value [Line Items]
Derivatives assets, Fair Value		$ 750		$ 750
Fixed interest rate percentage		5.25%		5.25%
Cash Flow Hedges [Abstract]
Derivative notional amount terminated							$ 500
Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member] | Interest Expense, Net [Member]
Effect of Fair Value Hedges on Results of Operations [Abstract]
Gains and losses due to changes in fair value of derivative instruments		$ (2)	4	$ (3)	(6)
Warrants [Abstract]
Gains and losses due to changes in fair value of derivative instruments		(2)	4	(3)	(6)
Interest Rate Swaps [Member] | Not Designated as Hedging Instrument [Member] | Interest Expense, Net [Member]
Effect of Fair Value Hedges on Results of Operations [Abstract]
Gains and losses due to changes in fair value of derivative instruments		0	(1)	0	(1)
Warrants [Abstract]
Gains and losses due to changes in fair value of derivative instruments		0	(1)	0	(1)
Notes [Member] | Designated as Hedging Instrument [Member] | Interest Expense, Net [Member]
Effect of Fair Value Hedges on Results of Operations [Abstract]
Gains and losses due to changes in fair value of derivative instruments		2	(4)	3	6
Warrants [Abstract]
Gains and losses due to changes in fair value of derivative instruments		2	(4)	3	6
Warrants [Member] | Other Income (Expense) [Member]
Effect of Fair Value Hedges on Results of Operations [Abstract]
Gains and losses due to changes in fair value of derivative instruments		(532)	559	(594)	849
Warrants [Abstract]
Gains and losses due to changes in fair value of derivative instruments		(532)	559	(594)	849
Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member] | Selling, General and Administrative Expenses [Member]
Effect of Fair Value Hedges on Results of Operations [Abstract]
Gains and losses due to changes in fair value of derivative instruments		(23)	(28)	(25)	(28)
Warrants [Abstract]
Gains and losses due to changes in fair value of derivative instruments		(23)	(28)	(25)	(28)
Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member] | Other Income (Expense) [Member]
Effect of Fair Value Hedges on Results of Operations [Abstract]
Gains and losses due to changes in fair value of derivative instruments		33	0	33	0
Warrants [Abstract]
Gains and losses due to changes in fair value of derivative instruments		33	0	33	0
Second Step Transaction Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member] | Other Income (Expense) [Member]
Effect of Fair Value Hedges on Results of Operations [Abstract]
Gains and losses due to changes in fair value of derivative instruments		0	(70)	0	(166)
Warrants [Abstract]
Gains and losses due to changes in fair value of derivative instruments		$ 0	$ (70)	$ 0	$ (166)
Warrants Exercisable in March 2016 [Member] | AmerisourceBergen Corporation [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price (in dollars per share)		$ 51.50		$ 51.50
Warrants Exercisable in March 2016 [Member] | AmerisourceBergen Corporation [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant issued to purchase common stock (in shares)		22,696,912		22,696,912
Warrants Exercisable in March 2017 [Member] | AmerisourceBergen Corporation [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price (in dollars per share)		$ 52.50		$ 52.50
Warrants Exercisable in March 2017 [Member] | AmerisourceBergen Corporation [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant issued to purchase common stock (in shares)		22,696,912		22,696,912
Other Current Assets [Member] | Basis Swaps [Member] | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivatives assets, Notional Amount	[1]					$ 1
Derivatives assets, Fair Value						0
Other Current Assets [Member] | Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivatives assets, Notional Amount	[1]	$ 465		$ 465		1,205
Derivatives assets, Fair Value		1		1		34
Other Non-currents Assets [Member] | Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivatives assets, Notional Amount	[1]	250		250		250
Derivatives assets, Fair Value		5		5		2
Other Non-currents Assets [Member] | Warrants [Member] | Not Designated as Hedging Instrument [Member]
Warrants [Abstract]
Derivative asset		1,546		1,546		2,140
Other Current Liabilities [Member] | Basis Swaps [Member] | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivatives assets, Notional Amount	[1]	2		2
Derivatives assets, Fair Value		1		1
Other Current Liabilities [Member] | Foreign Currency Forwards [Member] | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivatives assets, Notional Amount	[1]	768		768		495
Derivatives assets, Fair Value		$ 16		$ 16		$ 9
[1]	Amounts are presented in U.S. dollar equivalents.

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Recurring [Member] - USD ($) $ in Millions		Feb. 29, 2016	Aug. 31, 2015
Restricted Cash [Member]
Assets [Abstract]
Fair value of assets	[1]	$ 175	$ 184
Money Market Funds [Member]
Assets [Abstract]
Fair value of assets	[2]	2,659	2,043
Available-for-sale Investments [Member]
Assets [Abstract]
Fair value of assets	[3]	1,027	1,183
Interest Rate Swaps [Member]
Assets [Abstract]
Fair value of assets	[4]	5	2
Foreign Currency Forwards [Member]
Assets [Abstract]
Fair value of assets	[5]	1	34
Liabilities [Abstract]
Fair value of liabilities	[5]	16	9
Warrants [Member]
Assets [Abstract]
Fair value of assets	[6]	1,546	2,140
Basis Swaps [Member]
Liabilities [Abstract]
Fair value of liabilities	[5]	1
Level 1 [Member] | Restricted Cash [Member]
Assets [Abstract]
Fair value of assets	[1]	175	184
Level 1 [Member] | Money Market Funds [Member]
Assets [Abstract]
Fair value of assets	[2]	2,659	2,043
Level 1 [Member] | Available-for-sale Investments [Member]
Assets [Abstract]
Fair value of assets	[3]	1,027	1,183
Level 1 [Member] | Interest Rate Swaps [Member]
Assets [Abstract]
Fair value of assets	[4]	0	0
Level 1 [Member] | Foreign Currency Forwards [Member]
Assets [Abstract]
Fair value of assets	[5]	0	0
Liabilities [Abstract]
Fair value of liabilities	[5]	0	0
Level 1 [Member] | Warrants [Member]
Assets [Abstract]
Fair value of assets	[6]	0	0
Level 1 [Member] | Basis Swaps [Member]
Liabilities [Abstract]
Fair value of liabilities	[5]	0
Level 2 [Member] | Restricted Cash [Member]
Assets [Abstract]
Fair value of assets	[1]	0	0
Level 2 [Member] | Money Market Funds [Member]
Assets [Abstract]
Fair value of assets	[2]	0	0
Level 2 [Member] | Available-for-sale Investments [Member]
Assets [Abstract]
Fair value of assets	[3]	0	0
Level 2 [Member] | Interest Rate Swaps [Member]
Assets [Abstract]
Fair value of assets	[4]	5	2
Level 2 [Member] | Foreign Currency Forwards [Member]
Assets [Abstract]
Fair value of assets	[5]	1	34
Liabilities [Abstract]
Fair value of liabilities	[5]	16	9
Level 2 [Member] | Warrants [Member]
Assets [Abstract]
Fair value of assets	[6]	1,546	2,140
Level 2 [Member] | Basis Swaps [Member]
Liabilities [Abstract]
Fair value of liabilities	[5]	1
Level 3 [Member] | Restricted Cash [Member]
Assets [Abstract]
Fair value of assets	[1]	0	0
Level 3 [Member] | Money Market Funds [Member]
Assets [Abstract]
Fair value of assets	[2]	0	0
Level 3 [Member] | Available-for-sale Investments [Member]
Assets [Abstract]
Fair value of assets	[3]	0	0
Level 3 [Member] | Interest Rate Swaps [Member]
Assets [Abstract]
Fair value of assets	[4]	0	0
Level 3 [Member] | Foreign Currency Forwards [Member]
Assets [Abstract]
Fair value of assets	[5]	0	0
Liabilities [Abstract]
Fair value of liabilities	[5]	0	0
Level 3 [Member] | Warrants [Member]
Assets [Abstract]
Fair value of assets	[6]	0	$ 0
Level 3 [Member] | Basis Swaps [Member]
Liabilities [Abstract]
Fair value of liabilities	[5]	$ 0
[1]	Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
[2]	Money market funds are valued at the closing price reported by the fund sponsor.
[3]	Fair values of quoted investments are based on current bid prices as of the balance sheet dates. See Note 6, Available-for-Sale Investments for additional information.
[4]	The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information.
[5]	The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
[6]	Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen's common stock; AmerisourceBergen's common stock price at the valuation date; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.price at the valuation date; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.

Commitments and Contingencies (

Commitments and Contingencies (Details)	Feb. 29, 2016Lawsuit
Loss Contingencies [Line Items]
Number of lawsuits filed	10
Court of Chancery of the State of Delaware [Member]
Loss Contingencies [Line Items]
Number of lawsuits filed	8
State of Pennsylvania in the Court of Common Pleas of Cumberland County [Member]
Loss Contingencies [Line Items]
Number of lawsuits filed	1
Middle District of Pennsylvania [Member]
Loss Contingencies [Line Items]
Number of lawsuits filed	1

Retirement Benefits (Details)

Retirement Benefits (Details) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016USD ($)	Feb. 28, 2015USD ($)	Feb. 29, 2016USD ($)PensionPlan	Feb. 28, 2015USD ($)
Defined Benefit Plan Disclosure [Line Items]
Number of defined benefit pension plans | PensionPlan			2
Employer cash contributions to defined benefit pension plans			$ 9
Employee expected additional contribution in current fiscal year			66
Walgreen Profit Sharing Retirement Trust [Member]
Defined Contribution Plan Disclosure [Line Items]
Profit sharing provision expense	$ 53	$ 21	111	$ 54
Alliance Boots Retirement Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Cost recognized in the consolidated condensed statements of earnings	34	22	69	22
Boots and Other Pension Plans [Member]
Components of net periodic benefit costs [Abstract]
Service costs	0	1	2	1
Interest costs	77	53	159	53
Expected returns on plan assets	(62)	(43)	(127)	(43)
Settlements	0	1	0	1
Total net periodic pension costs	15	12	34	12
Postretirement Health Benefit Plan[Member]
Components of net periodic benefit costs [Abstract]
Service costs	2	2	5	5
Interest costs	5	4	10	8
Amortization of actuarial loss	5	5	9	10
Amortization of prior service cost	(7)	(6)	(14)	(12)
Total net periodic pension costs	$ 5	$ 5	$ 10	$ 11

Earnings Per Share (Details)

Earnings Per Share (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Earnings Per Share [Abstract]
Antidilutive securities excluded from EPS calculations (in shares)	3.2	3.4	2.2	5

Depreciation and Amortization70

Depreciation and Amortization (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Depreciation and Amortization [Abstract]
Depreciation expense	$ 346	$ 311	$ 644	$ 567
Intangible asset and other amortization	96	196	180	259
Total depreciation and amortization expense	$ 442	$ 507	$ 824	$ 826

Supplemental Cash Flow Disclo71

Supplemental Cash Flow Disclosures (Details) - USD ($) $ in Millions	6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
Supplemental Cash Flow Disclosures [Abstract]
Cash paid for interest	$ 302	$ 90
Cash paid for income taxes	$ 481	$ 553

Accumulated Other Comprehensi72

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Feb. 29, 2016	Feb. 28, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ (658)	$ 54	$ (214)	$ 136
Other comprehensive income (loss) before reclassification adjustments	(1,264)	(313)	(1,715)	(436)
Amounts reclassified from accumulated OCI	2	309	3	309
Tax benefit (provision)	52	(118)	58	(77)
Net other comprehensive income (loss)	(1,210)	(122)	(1,654)	(204)
Ending Balance	(1,868)	(68)	(1,868)	(68)
Pension/Post-retirement Obligations [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	32	14	29	15
Other comprehensive income (loss) before reclassification adjustments	(4)	(8)	(1)	(10)
Amounts reclassified from accumulated OCI	0	0	0	0
Tax benefit (provision)	2	0	2	1
Net other comprehensive income (loss)	(2)	(8)	1	(9)
Ending Balance	30	6	30	6
Unrecognized Gain (Loss) on Available-for-Sale Investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	260	206	259	107
Other comprehensive income (loss) before reclassification adjustments	(139)	140	(144)	297
Amounts reclassified from accumulated OCI	0	0	0	0
Tax benefit (provision)	51	(50)	57	(108)
Net other comprehensive income (loss)	(88)	90	(87)	189
Ending Balance	172	296	172	296
Unrealized Gain (Loss) on Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(39)	(39)	(40)	(27)
Other comprehensive income (loss) before reclassification adjustments	0	2	0	(18)
Amounts reclassified from accumulated OCI	2	(1)	3	(1)
Tax benefit (provision)	(1)	(1)	(1)	7
Net other comprehensive income (loss)	1	0	2	(12)
Ending Balance	(38)	(39)	(38)	(39)
Share of Alliance Boots OCI [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(92)		(113)
Other comprehensive income (loss) before reclassification adjustments		(89)		(57)
Amounts reclassified from accumulated OCI		230		230
Tax benefit (provision)		(49)		(60)
Net other comprehensive income (loss)		92		113
Ending Balance		0		0
Cumulative Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(911)	(35)	(462)	154
Other comprehensive income (loss) before reclassification adjustments	(1,121)	(358)	(1,570)	(648)
Amounts reclassified from accumulated OCI	0	80	0	80
Tax benefit (provision)	0	(18)	0	83
Net other comprehensive income (loss)	(1,121)	(296)	(1,570)	(485)
Ending Balance	$ (2,032)	$ (331)	$ (2,032)	$ (331)

Segment Reporting (Details)

Segment Reporting (Details) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 29, 2016USD ($)	Feb. 28, 2015USD ($)	Feb. 29, 2016USD ($)Segment	Feb. 28, 2015USD ($)	Dec. 31, 2014
Segment Reporting [Abstract]
Number of reportable segments | Segment			3
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	$ 30,184	$ 26,573	$ 59,217	$ 46,127
Adjusted Operating Income	2,120	1,840	3,839	2,958
Acquisition-related amortization	(101)	(217)	(182)	(306)
Cost transformation	(28)		(118)
LIFO provision	(68)	(55)	(114)	(107)
Store closures and other optimization costs		(16)		(44)
Acquisition-related costs	(33)	(59)	(67)	(83)
(Decrease) increase in fair market value of warrants		(6)		123
Asset impairment	(30)	(110)	(30)	(110)
Operating Income	$ 1,860	1,377	$ 3,328	2,431
Alliance Boots [Member]
Segment Reporting Information [Line Items]
Equity interest in Alliance Boots	45.00%		45.00%		45.00%
Walgreens Boots Alliance [Member]
Segment Reporting Information [Line Items]
Ownership percentage of WBA					55.00%
Retail Pharmacy USA [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	$ 21,500	21,048	$ 41,870	40,602
Adjusted Operating Income	1,632	1,598	2,875	2,716
Acquisition-related amortization	0
Retail Pharmacy International [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	3,689	2,047	7,220	2,047
Adjusted Operating Income	335	125	650	125
Acquisition-related amortization	0
Pharmaceutical Wholesale [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	5,627	3,865	11,423	3,865
Adjusted Operating Income	155	121	321	121
Acquisition-related amortization	0
Eliminations and Unallocated Items [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	(632)	(387)	1,296	(387)
Adjusted Operating Income	(2)	(4)	(7)	(4)
Acquisition-related amortization	0
Reportable Segments [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	30,184	26,573	59,217	46,127
Adjusted Operating Income	2,120	1,840	3,839	2,958
Reportable Segments [Member] | Retail Pharmacy USA [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	21,500	21,048	41,870	40,602
Adjusted Operating Income	1,632	1,598	2,875	2,716
Reportable Segments [Member] | Retail Pharmacy International [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	3,627	2,017	7,084	2,017
Adjusted Operating Income	335	125	650	125
Reportable Segments [Member] | Pharmaceutical Wholesale [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	5,057	3,508	10,261	3,508
Adjusted Operating Income	155	121	321	121
Reportable Segments [Member] | Eliminations and Unallocated Items [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	0	0	0	0
Intersegment Eliminations [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	0	0	0	0
Intersegment Eliminations [Member] | Retail Pharmacy USA [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	0	0	0	0
Intersegment Eliminations [Member] | Retail Pharmacy International [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	62	30	134	30
Intersegment Eliminations [Member] | Pharmaceutical Wholesale [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	570	357	1,162	357
Intersegment Eliminations [Member] | Eliminations and Unallocated Items [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales	$ (632)	$ (387)	$ 1,296	$ (387)

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event [Member] - AmerisourceBergen Common Stock [Member] $ in Millions	Mar. 18, 2016USD ($)shares
Subsequent Event [Line Items]
Warrant exercised to purchase common stock (in shares)	22,696,912
Warrants aggregate exercise price payment | $	$ 1,170
Outstanding shares owned (in shares)	34,157,955
Percentage of outstanding common shares owned	15.20%